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SUMMARY
It is now well recognised that in uveal melanoma and specifically choroidal 
melanoma, monosomy 3 has a stronger association with death caused by métastasés 
than clinical and histological parameters. However, the identification of the presence 
or absence of monosomy 3 and its correlation with morphological heterogeneity 
within tissue sections has not been assessed. Furthermore, the role of monosomy 3 in 
predicting time to death is not fully understood. All these aspects have been 
investigated in more detail in this thesis.
In the introduction to this thesis previously published work concerning new and well- 
established prognostic factors in choroidal melanoma is reviewed. Diagnostic 
modalities including cytogenetic studies and treatment of this malignant neoplasm 
and its metastatic disease are also discussed.
In the first study of this thesis the teehnique of chromosome in situ hybridisation 
(CISH) was adapted to allow its application to archival choroidal melanoma, which 
was both formalin and gluteraldehyde fixed. The advantage of this technique 
compared with other techniques available is that it is applicable to archival material 
allowing the direct correlation of chromosomal changes with histology. CISH was 
shown to be an effective method for assessing monosomy 3 in these archival paraffin 
embedded tissue sections. The efficiency of the CISH technique was compared with 
fluorescence in situ hybridisation (FISH). The main additional advantage of FISH is 
that it is possible to assess the copy number of several chromosomes at one time.
However, a consistent signal could not be obtained with FISH in archival tissue thus 
the CISH technique was adopted for further study of archival choroidal melanoma.
The CISH technique was then used to assess the presence or absence of monosomy 3 
in an archival series of melanoma examining tumours from individuals that had died 
from metastatic melanoma and comparing them with individuals that had survived.
The results confirmed the work of previous studies that monosomy 3 is an important 
predictor of death in choroidal melanoma. However, this study also showed that 
disomy 3 does not guarantee survival since a small group of tumours displaying 
disomy 3 resulted in metastatic death. The reasons for this may be related to the 
inclusion criteria used in this investigation since this was a retrospective study.
Furthermore, with the CISH technique used in this study the probes were centromere 
specific and regional losses of chromosome 3 might not have been detected.
However, regional losses seem to occur only in a minority of cases. Finally, and 
probably more likely, there are additional alterations that allow invasion and 
métastasés in choroidal melanoma. This study also showed that monosomy 3, in 
some cases, could also be predicted from histology, particularly by the presence of 
epithelioid cells and vascular loops. One advantage of this archival series was the 
long follow up available such that late deaths from metastatic melanoma were 
represented (the longest time to death for metastatic melanoma was 14 years) as well 
as those that succumbed to métastasés at around 3 years. Additional this study |
showed that monosomy 3 does not influence time until death as there was no 
significant difference in this interval between metastatic melanomas, with and 
without monosomy 3.
Another advantage of CISH is that it is possible to assess chromosome copy number 
in conjunction with cell morphology. This aspect of the technique was assessed in 
the final study of this thesis. A group of choroidal melanomas with well-defined 
populations of epithelioid and spindle cells were identified from the original study 
group. Counting was undertaken within these defined morphological populations and 
monosomy 3 was heterogeneous in a subpopulation of these choroidal melanomas 
occurring in epithelioid but not spindle shaped cells. This has implications for 
cytogenetic screening for monosomy 3 since the genetic information obtained from 
small samples may not be representative. Therefore, a sample composed purely of 
spindle cells might caiTy less prognostic significance than one containing both 
spindle and epithelioid cells.
In conclusion, CISH has proven a valuable additional technique allowing 
retrospective studies of monosomy 3 in choroidal melanoma therefore including 
larger numbers than most prospective studies and a longer follow-up. Utilising CISH 
has provided important additional information concerning the significance of 
monosomy 3 in choroidal melanoma.
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1 INTRODUCTION
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1.1 Epidemiology, Environmental and Host Risk Factors for 
Choroidal Melanoma
Choroidal melanoma is part of the melanomas of the uveal tract and is the most 
common primary intraocular malignancy in adults, with an overall estimated 
incidence of six cases per one million subjects per year in the western world (Teikari 
and Raivio, 1985, Swerdlow, 1983, Singh and Topham, 2003, Mooy and De Jong, 
1996, Jensen, 1963, Gislason et al., 1985, Bergman et a l, 2002). The reported 
incidence rate of uveal melanoma has ranged from 0.3 to 9.1 cases per million and 
these differences are attributed to variations in inclusion and methods used in the 
different studies (Table 1.1).
Table 1.1 Mean age-adjusted incidence of uveal melanoma in different 
countries (adapted from Singh & Topham, 2003)
REGION INCIDENCE 
PER 1000000
REFERENCES
Norway 9.0 Mork, 1961
Denmark 7.4 Jensen, 1963
England (UK) 6.4 Swerdlow, 1983
Iceland 6.0 Gislason et al, 1985
Finland 7.6 Teikari & Raivio, 1985
Japan 0.3 Kaneko, 1993
Sweden 9.1 Bergman et al, 2001
United States 4.3 Singh & Topham, 2003
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Large studies indicate a slight male predominance but the reason for this is unknown 
(Singh and Topham, 2003, Bergman et a l, 2002). Unlike UV-induced cutaneous 
melanoma which has shown a marked increase in incidence in white populations 
during the past decade (Bergman et ah, 2006), the incidence of choroidal melanoma 
has not increased (Singh and Topham, 2003, Bergman et ah, 2002). However the 
incidence of choroidal melanoma does vary between different groups studied and 
appear to be influenced by race, geographical location and a genetic predisposition 
(Bergman et ah, 2002). For example, the incidence in whites is eight times that in 
blacks and it occurs most frequently in elderly white-skinned individuals (Egan et 
ah, 1988). Geographically, the incidence of ocular melanoma is also higher in |
northern countries compared with southern countries. This may be because northern 
populations tend to have a fair complexion with light iris colour and these features 
are considered to be strong risk factors for choroidal melanoma (Bergman et ah,
2002). Family history of uveal melanoma is rare (0.6% of all uveal melanoma cases) 
and so far seventy three families with uveal melanoma (including ciliary body and 
choroidal melanomas) have been reported in the literature (Kodjikian et ah, 2003).
Furthermore, the mode of inheritance still requires to be established in these familial 
cases. Patients with a family history of melanoma have also been reported to have a 
4-fold greater risk for second primary malignant neoplasms. (Singh et ah, 1996).
Choroidal naevus is one of the best documented predisposing lesions for choroidal 
melanoma. Although the risk of choroidal melanoma in individuals with choroidal 
naevus is low, this risk seems to be much greater than the risk in individuals without 
choroidal naevus. It has been reported that 1 in 5000 people with choroidal naevus 
will develop a melanoma each year. (Egan et ah, 1988). Predisposing factors for 
choroidal melanoma also include congenital ocular melanocytosis (naevus of Ota)
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(Velazquez and Jones, 1983, Egan et a l, 1988), neurofibromatosis type 1 (Antle et 
a l, 1990) and familial atypical mole and melanoma (FAM-M) syndrome (previously 
called dysplastic naevus syndrome) (Singh et a l, 1996, Egan et a l, 1988).
1.2 Prognostic Indicators of Choroidal Melanoma
1.2.1 Background
Choroidal melanoma is characterised by an unpredictable clinical course with an 
overall 5- and 10-year survival of 74 % and 55%, respectively (Seddon et a l, 1983). 
There are various clinical and pathological features which are predicators of survival 
but these are unreliable in individual cases. Death is usually due to liver métastasés 
(Diener-West et a l, 1992, Mooy and De Jong, 1996) and the median survival time 
for a patient with liver métastasés is only 7 months (Kath et a l, 1993). The peak 
mortality from metastatic disease occurs within 3 yeai's of diagnosis but métastasés 
can occur late up to 36 years later (Newton, 1965, McLean et a l, 1982).
1.2.2 Clinical Prognostic Parameters 
Age
Choroidal melanoma is very rare in childhood and the incidence increases with age 
reaching a peak in late middle age (Egan et a l, 1988). Kaplan Meier survival curves 
comparing younger with older patients show that long-term survival rates do not 
differ significantly (McLean, 1995). This suggests that the cure rates for the two
19
groups are similar. Therefore the differences in survival may be due to more rapid 
death in older patients with metastatic melanoma (McLean et al., 2004).
Tumour size
One of the most consistent prognostic indicators for métastasés of choroidal 
melanoma is tumour size (Gamel et al., 1992, McLean et al., 1982, Coleman et al., 
1993, Damato et al., 1996). The clinical tumour size may be defined as small (3mm 
or less in thickness and smaller than 10mm diameter), medium (between 3 and 5 mm 
in thickness and/or between 10 and 15 mm in diameter), or large (greater than 5 mm 
in thickness and/or greater than 15mm in diameter) (Shields et al., 1991). McLean 
and associates (McLean et al., 1982) also found that the largest tumour dimension 
correlated better with survival than the thickness of the tumour. Multivariate analysis 
in different studies found the largest tumour dimension to be a significant 
independent variable (Seddon et al., 1983, Coleman et al., 1993, Affeldt et al., 
1980). In the study by Seddon et al. larger tumours were more likely to be anteriorly 
located and occur in patients with a history of glaucoma (Seddon et a i, 1983). 
Overall, larger tumours carry a worse prognosis but small tumours have also been 
shown to cause death by métastasés (Shields et al., 1995a) (Figure 1.1). In a study by 
Diener-West et al., the 5-year mortality rates following enucleation were 16% for 
small tumours (largest tumour diameter-LTD- <10mm), 32% for medium (LTD 10- 
15mm), and 53% for large (LTD>15mm) tumours (Diener-West et al., 1992).
20
Figure 1.1 Choroidal melanoma gross pathology. A: large tumour. B: 
small tumour
The large tumour (A) has also presented with extraocular extension (arrow).
21
1.2.3 Histopathological Prognostic Parameters 
Cell type
Cell type appears to be one of the most consistent prognostic factors. In the most 
commonly used modified Callender classification of uveal melanomas, the 
morphology of the cells is classified as spindle, epithelioid, or mixed (spindle and
22
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Tumour location
When a choroidal melanoma that invades the ciliary body is diagnosed, the original 
uveal location where the tumour initiated may be difficult to resolve but is usually 
considered choroidal if the tumour is located predominantly in the choroid. The 
location of the anterior margin of the tumour was considered an important 
independent predictor of outcome in the study by Seddon et al. (Seddon et at., 1983). 
In the same study, tumours were coded as follows: posterior to the equator, anterior 
to the equator without involvement of the ciliary body, and anterior to the equator 
involving the ciliary body; choroidal tumours involving the ciliary body had the 
worst prognosis, followed by those choroidal tumours not involving the ciliary body 
but anterior to the equator. Packard similarly showed a poorer survival for anteriorly 
placed choroidal tumours (Packard, 1980). Choroidal tumours extending to the 
ciliary body tend to be larger than posterior ones (posterior to the equator), but 
tumour size alone does not explain the association with poorer survival (Seddon et 
at., 1983). For posteriorly located tumours, those located adjacent to the optic disc 
have a worse prognosis, related to more frequent extrascleral extension (Affeldt et 
a l, 1980).
epithelioid) (McLean et a l, 1983) (Figure 1.2). Pure spindle cell uveal melanoma has 
the best prognosis, pure epithelioid cell melanoma the worst, and mixed cell 
melanoma an intermediate prognosis (McLean et a l, 1982). Seddon et a l  attempted 
to define the amount of epithelioid cells required to infer a poor prognosis and 
concluded that more than two epithelioid cells present per high-power microscopic 
field (HPF) was sufficient (Seddon et a l, 1983). In this study, the number of 
epithelioid cells/HPF was interrelated with other variables but on multivariate 
analysis it was an independent risk factor. Thus, tumours with a higher number of 
epithelioid cells were also larger, more anteriorly located and had more mitotic 
figures. Cell type has also been recognised as an independent factor in other series 
(Seddon et a l, 1987, Moshari et a l, 2001, McLean et a l, 1977, Damato et a l, 1996, 
Coleman et a l, 1993, Affeldt et a l, 1980). Occasionally balloon cells, similar to 
those in cutaneous melanoma may be identified in some uveal melanomas. Their 
nature and importance is controversial. It has been suggested that they may represent 
spindle melanoma cells that have undergone extensive cytoplasmic lipid degradation; 
however this was not confirmed by electron microscopy (EM) (Jakobiec et a l, 
1979). An EM study of 3 patients with balloon cell melanoma of the choroid 
revealed premelanosomes and complex melanosomes in the cytoplasm of balloon 
cells without evidence of significant lipid (Rodrigues and Shields, 1976). Lane et a l 
found a higher number of balloon cells in irradiated tumours (Lane et a l, 1997) and 
Jakobiec et a l  found that melanomas with prominent balloon cells had a better 
prognosis (Jakobiec et a l, 1979). Conversily Khalil concluded that the presence of 
balloon cells does not alter the prognosis (Khalil, 1983).
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Nuclear and nucleolar size
Although the reproducibility of the modified Callender cell type classification 
(McLean et al., 1983) has been shown, several studies have indicated that objective 
measurements such as nuclear and nucleolar area from randomly selected cells are 
better predictors of patient outcome than Callender’s cell type (Gamel et aL, 1992, 
McLean and Gamel, 1988, Gragoudas et ah, 1987). In particular, the mean of ten 
largest nucleoli and the standard deviation of nucleolar area have been shown to be 
prognostically significant (Gragoudas et ah, 1987, Gamel et ah, 1992). These 
techniques are however labour intensive and the selection of cells for measurement is 
still subjective.
24
4Figure 1.2 Three different celi type tumours.
H&E stained sections (x 400) illustrating the three main choroidal m elanom a cell 
types. A: Epithelioid cell type tumour. B: Spindle cell type tumour. C: M ixed cell 
type tumour with epithelioid cells (sm all arrow) and spindle cells (large arrow).
25
Microvascular patterns and microvascular density (MVD)
The prognostic significance of microvessels in uveal melanoma has been assessed in 
a number of studies that have included quantitative variables such as microvascular 
density (MVD) (Makitie et al., 1999a, Lane et al., 1997, Foss et a l, 1997, Foss,
1996) and qualitative ones such as microvascular patterns that are used to assess the 
arrangement of the microvessels (Folberg et a l, 1992, Folberg et a l,  1993, Foss et 
a l, 1997, Kivelà et a l, 2004, Makitie et a l, 1999b, McLean et a l, 1997).
Microvascular patterns
Microvascular patterns are three dimensional architectural arrangements of 
microvessels and extravasculai' matrix in uveal melanoma and were introduced by 
Folberg et al. in 1992 when they presented nine morphological types of microvessel 
architecture (Folberg et a l, 1992). The patterns can be identified by periodic acid 
Schiff stain (PAS) without hematoxylin counterstain (Folberg et ah, 1992). PAS also 
stains melanoma cells, but the use of green filter enhances contrast of PAS-positive 
structures helping in recognition of microvessels (Folberg et al., 1992). The 
incidence of vascular loops in uveal melanoma is reported to be approximately 60% 
(Folberg et a l, 1993, Foss et a l, 1997, Kivelâ et a l, 2004). According to the original 
classification (Folberg et a l,  1992) the normal pattern consists of normal 
uncompressed choroidal vessels. The silent pattern consists of no apparent tumour 
vessels. The straight pattern comprises randomly oriented straight vessels that are not 
linked with each other. The parallel pattern included straight vessels that are aligned 
parallel to each another. The parallel with cross-link pattern contains vessels of
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parallel pattern that are also linked to each other. The arcs and arcs with branching 
patterns are incomplete loops. The loop pattern consists of vessels that form a 
completely enclosed loop (Figure 1.3). The network pattern is composed of at least 
three back-to-back closed loops. By definition, if networks are present, loops are 
present (Folberg et a l, 1992). In a follow up study of 234 patients Folberg et al. 
showed that patients who survived over 10 years had tumours that less frequently 
displayed the following patterns: parallels with cross-linking, loops and networks 
(Folberg et al., 1993). In the same study, using multivariate analysis, the presence of 
networks and parallel vessels with cross-links were independent prognostic factors. 
Parallel with cross-linking, loops and networks have also shown a strong association 
with other potential prognostic factors such as epithelioid cells and tumour- 
infiltrating lymphocytes (Folberg et al., 1993). Other studies have shown that 
patients with tumours containing networks and parallel vessels with cross-linking 
that occupy 2% of cross-sectional have a significantly worse prognosis that do those 
patients with tumours containing a smaller percentage of these patterns (Mehaffey et 
aL, 1997). Further studies have shown that tumour cells of malignant uveal and 
metastatic cutaneous melanoma are able to form microvascular patterns, in particular 
microvascular loops and networks in vitro without presence of endothelial cells 
(Folberg et al., 2000). This concept of vessel formation without endothelial cells is 
called “vasculogenic mimicry” (Maniotis et aL, 1999).
The results of these experiments suggest that the generation of these channel like 
structures is associated with remodelling of extracellular matrix with overexpression 
of genes that regulate relevant molecules such as collagen VI (Maniotis et al., 1999, 
Daniels et al., 1996).
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Figure 1.3 Microvascular loops. A&B: PAS-stained choroidal melanoma 
showing loops (x250)
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Whilst the majority of researchers have shown that vascular loops carry a poor 
prognosis, opinions differ as to the nature and function of the vascular loops. Folberg 
et al. defined them as periodic acid-Schiff-positive patterns representing blood 
vessels (Folberg et aL, 1993), but according to Foss et al. they are formed from 
connective tissue (Foss et aL, 1997). However both groups associated vascular loops 
with a poor prognosis. A few researchers have disputed this and found no such 
associations (Seregard et aL, 1998, Lane et aL, 1997).
Microvascular density (MVD)
Microvessel density (MVD) reflects the proliferation of capillary endothelium within 
the tumours (Foss et aL, 1997) and high MVD has been shown to be an important 
prognostic factor for a number of cancers (Makitie et aL, 1999a). Studies have 
reported that high MVD is associated with a shortened survival of patients with uveal 
melanoma and is higher in tumours with microvascular loops and networks (Makitie 
et aL, 1999a, Foss et aL, 1997). Conversely, Lane et aL failed to document any 
survival difference between tumours with different micro vessel counts (Lane et aL,
1997).
Necrosis
The cause of necrosis in melanomas is still unclear but tends to occur in large 
tumours that have outgrown their blood supply. Immunity may also play a role 
(Moshaii et aL, 2001). Around 7% of choroidal and ciliary body melanomas show
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total necrosis. Several investigators have studied the effect of both partial and total 
necrosis on survival and concluded that tumour necrosis was not an independent 
prognostic factor (Moshari et aL, 2001, de la Cruz et aL, 1990, COMS, 1998 a). The 
COMS study (COMS, 1998 a) and de la Cruz et al (de la Cruz et aL, 1990) graded 
the necrotic tumours in 4 categories depending on the area affected by necrosis. In 
the COMS study (COMS, 1998 a), necrosis was associated with large tumour size 
and epithelioid cell type.
Intermediate filaments
Interaction between tumour cells and surrounding stroma are considered essential for 
tumour progression and dissemination. Hendrix et al. performed 
immunohistochemistry for vimentin and cytokeratin in uveal melanoma. Vimentin is 
an intermediate filament common to mesenchymal tissues but also present in uveal 
melanoma whereas carcinomas typically express keratin, which is a epithelial marker 
(Hendrix et aL, 1998). They defined cells that coexpressed both vimentin and 
cytokeratin (CK) as “interconverted” and suggested that this indicated metastatic 
potential (Hendrix et aL, 1998). However in a study of 52 uveal melanomas Fuchs et 
a l  showed that whilst all cases were positive for vimentin, 48.1% showed 
immunoreactivity for different subtypes of CK (Fuchs et aL, 1992). Although 
métastasés were more common when the primary tumour was immunoreactive for 
CKs, this was related to the fact that CKs positivity was more frequent in mixed and 
epithelioid cell melanomas (Fuchs et aL, 1992).
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Cell-matrix interaction
Cell adhesion molecules are membrane receptors involved in various cellular 
processes, including tumorigenesis. Of these, loss of intercellular cell adhesion 
molecule-1 has been linked to the development of métastasés within the first 5 years 
of diagnosis (Anastassiou et a i,  2000). Conversely, Woodward et al. showed that 
invasive melanoma cell lines expressing al-and a4-integrins displayed better 
adhesion to extracellular matrix substrates and endothelial cells than noninvasive cell 
lines that did not display those integrins (Woodward et aL, 2005).
Matrix metalloproteinases (MMPs) are secreted by tumour cells and play a role in 
degrading the extracellular matrix (Vaisanen et aL, 1999). Expression of matrix 
metalloproteinsase-2 (MMP-2) has been linked with decreased uveal melanoma 
survival (Vaisanen et aL, 1999).
The expression of epidermal growth factor receptor (EGFR) and insulin-like growth 
factor-1 receptor (IGF-IR) in uveal melanoma cell lines have also been shown to 
correlate with metastatic potential (All-Ericsson et aL, 2002, Hurks et aL, 2000). In 
an increasing number of malignant cell types, IGF-IR has been shown to be essential 
for tumorigenesis as well as for the establishment and maintenance of a transformed 
phenotype (All-Ericsson et aL, 2002). All-Ericsson et aL studied the expression of 
IGF-IR in 36 uveal melanomas. This was present in 94.4% of cases and high levels 
of expression were associated with a decreased survival (All-Ericsson et aL, 2002).
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Markers of cell proliferation
Mitotic rate in uveal melanomas is remarkably unpredictable but appears to be of 
prognostic value in several studies (Folberg et ah, 1992, McLean et aL, 1977). 
McLean et aL observed a correlation between tumour mitotic activity and mortality 
(McLean et aL, 1977). Mitotic activity was determined by counting the number of 
mitotic figures in 40 high power fields (HPFs). However more recently it has been 
suggested that the use of undefined HPFs introduces subjective variability and makes 
comparisons between centres difficult and as such it has been recommended that 
mitotic counts are expressed per mm^ (Mudhar et aL, 2004).
Cells that are in the proliferative phase of the cell cycle can be characterised with 
antibodies to proteins such as the proliferating cell nuclear antigen (PCNA) and Ki- 
67. Seregard et al  reported that a high count of PCNA-positive cells was associated 
with an increased risk of métastasés (Seregard et aL, 1996) but conversely Karlsson 
et al did not find any association between (PCNA) positivity and survival (Karlsson 
et aL, 1996). In this latter study, a high level of Ki-67 positivity was associated with 
large epithelioid cell tumours and therefore a shorter survival.
Tumour pigmentation
Heavy tumour pigmentation has been associated with a decreased survival in several 
univariate studies (Seddon et aL, 1983, McLean et aL, 1977) but different 
classifications of the amount of pigmentation make comparisons between these 
studies difficult. However the relationship between heavy tumour pigmentation and
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two other prognostic indicators such as epithelioid cell type and large tumour size 
suggests that the prognostic significance of tumour pigmentation may be secondary 
to other tumour characteristics (COMS, 1998 a).
Retinal detachment
Exudative retinal detachment (RD) is detected clinically in up to 75% of eyes with 
malignant uveal melanoma, and it is the most common abnormality that accompanies 
this tumour (Kivela et aL, 2001). Exudative RD in conservatively managed eyes with 
uveal melanoma has also been associated with the rapidity of growth and the extent 
of necrosis of the tumour (Kivela et aL, 2001). Therefore RD is an established 
marker of clinical disease activity (Shields et aL, 1995a) but the influence on survival 
remains controversial (Coleman et aL, 1993, Shields et aL, 1995a). Kivela et al have 
showed that in a study of 142 cases of uveal melanoma, associated RD was not an 
independent prognostic factor; however tumour size and vascular loops were strong 
predictors of exudative RD in that study. (Kivela et aL, 2001).
1.2.4 Clinicopathological Prognostic Parameters 
Extraocular extension
The fibrous layer of the eye, the sclera, provides a hairier to the growth of intraocular 
melanoma but intraocular melanoma can invade the sclera through the emissaries 
channels including the vortex veins and the ciliary arteries and nerves (McLean et 
aL, 2004). The reported incidence of extrascleral extension of uveal melanomas
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ranges from 10-15% (Affeldt et al., 1980, Shammas and Blodi, 1977). Large 
intraocular tumours are more likely to be accompanied by extrascleral extension of 
the primary (Shammas and Blodi, 1977) but small melanomas invading outside the 
eye have been reported and may produce an extraocular mass bigger than the 
intraocular portion of the tumour (Sassani et aL, 1985, Coleman et aL, 1993). 
Peripapillary choroidal melanomas frequently invade the optic nerve head but only 
rarely extend significantly posterior to the lamina cribrosa (McLean et aL, 2004). It 
remains unclear whether there is a difference in prognosis between extraocular 
spread via the vortex veins compared with direct infiltration through the sclera 
(Mudhar et aL, 2004). Extrascleral extension has been reported to be higher in 
pathological series because both microscopic and nodular forms of transcleral 
tumour extension are included compared with clinical series that consider only 
lesions visible pre- or intraoperatively (Augsburger et al,  2004b, De Potter et al,
1996) (Figure 1.4).
In the COMS study (COMS, 1998 a), extraocular extension was an unfavourable 
prognostic sign and the presence of extraocular extension was observed in about 8% 
of enucleated eyes. In a study by Seddon et aL the 10 year mortality was doubled to 
about 75% compared with cases with no extraocular extension (Seddon et aL, 1983). 
In the study by Affeldt et al. (Affeldt et al., 1980), although patients demonstrating 
extrascleral extension carried an overall poor prognosis, approximately 1/3 survived 
for 20 years without métastasés or died of non-tumour-related causes.
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Figure 1.4 Macroscopic specimens after extended enucleation 
secondary to choroidal melanoma. A: tumour showing orbital mass 
adherent to outer aspect of scleral layer; B: tumour showing optic 
nerve and scleral invasion.
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1.2.5 Immune responses in choroidal melanoma
The role of the immune system in the development of métastasés is unclear and it 
remains uncertain whether tumour infiltrating lymphocytes (TILs) play a significant 
role in tumour related immunity. Lymphocytic infiltration in the COMS study was 
not an independent prognostic factor but in this study spindle cell type tumours had 
the least inflammation and epithelioid cell tumours the greatest degree of 
infianamation (COMS, 1998 a). About 5-12% of uveal melanomas show evidence of 
TILs; these are mostly T cells and their presence may reflect the degree of tumour 
antigen expression (Durie et ah, 1990). In another study, from the AFIP (de la Cruz 
et aL, 1990) the presence of more than 100 TILs per 20 HPFs was associated with a 
decreased survival; the survival rate at 15 years of patients with tumours containing a 
high lymphocytic count was 36.7% compared with 69.6% for the patients with a low 
lymphocytic count. An immunohistochemical analysis of TIL revealed that T cells 
predominated in 73.8% of the tumours; B cells were observed less often (in 14% of 
patients) (Whelchel et aL, 1993). In this study T-lymphocytic infiltration was 
associated with métastasés. The number of TILs has been correlated with HLA 
expression by the uveal melanoma (de Waard-Siebinga et aL, 1996) and an 
association between high HLA class I antigen expression in uveal melanoma lesions 
and poor prognosis has been suggested (Ericsson et aL, 2001, Blom et aL, 1997). It 
has also been suggested that changes in expression of the class I molecules can 
influence the development of métastasés through a direct effect on the susceptibility 
of tumour cells lysis by natural killer (NK) cells. Therefore, uveal melanoma cells 
with a low HLA Class I expression would be killed by NK cells before they reach the 
liver (Blom etaL, 1997).
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1.2.6 DNA aneuploidy
DNA quantification can be carried out by flow cytometry to determine the nuclear 
DNA content (ploidy) and proliferative activity of tumour cells (Mooy and De Jong,
1996). Tumour cells may have a noncomplementary amount of DNA (aneuploid) and 
this is considered to reflect genetic instability and impaired cell cycle control (Mooy 
and De Jong, 1996). DNA aneuploidy has been associated with the epithelioid cell 
type (Mooy et aL, 1995a).
1.2.7 Oncogene activation
C-myc is an oncogene involved in cell proliferation and located on chromosome 8; 
abnormalities in this gene have been linked to uveal melanoma (Saraiva et aL, 2004). 
A high expression of the c-myc oncogene is known to be associated with poor 
survival in cutaneous melanoma (Tulley et aL, 2003). Conversely in uveal 
melanoma, a low expression of c-myc is associated with higher mortality (Ghana et 
al,  1998). Interferon has been used as an adjuvant agent in uveal melanoma and 
there is some evidence suggesting that c-myc has an important role in the action of 
interferon alpha. Overexpression of the c-myc gene, and the subsequent failure to 
downregulate its expression seems to be associated with interferon resistance. 
(Tulley et aL, 2003).
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1.2.8 Programmed cell death
Uveal melanomas can express p53, a tumour suppressor gene whose protein product 
induces apoptosis and cell-cycle arrest; abnormalities of this gene are present in 
many cancers. (Saraiva et aL, 2004). Expression of Bcl-2, a proto-oncogene that 
inhibits programmed cell death has shown no prognostic significance in uveal 
melanoma (Mooy et aL, 1995b). In a study by Coupland et al high levels of p53 
expression were associated with the presence of métastasés at 5 years (Coupland et 
aL, 2000). Somatostatin can induce arrest of cell growth and/or apoptosis by binding 
a membrane receptor. Ardjomand et al found high levels of somatostatin receptor-2 
to be significantly associated with longer survival (Ardjomand et aL, 2003)
1.2.9 Chromosomal abnormalities
Cytogenetic analysis of uveal melanoma has identified several nonrandom 
chromosomal aberrations, that appear to correlate better with prognosis than clinical 
and pathological features (White et a l ,  1998, Vajdic et a l ,  2003, Speicher et al, 
1994, Sisley et al, 1997, S choies et a l,  2003, Prescher et a l ,  1996, Près cher et al, 
1990, Aalto et a l,  2001) (Table 1.2). Among the most important genetic changes 
observed are loss of an entire chromosome 3 homologue (monosomy 3). This has 
been shown to be present in around 50% of choroidal melanomas (White et a l ,  1998, 
Sisley et a l ,  1997, Prescher et a l ,  1996, Gordon et al,  1994). Monosomy 3 has been 
shown to be a significant predictor of poor prognosis in several studies of uveal 
melanoma (White et aL, 1998, Sisley et aL, 1997, Sisley et aL, 2000, Prescher et aL, 
1996, Kilic et aL, 2005, Aalto et aL, 2001) and it is also often associated with an
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increase in chromosome 8q. (Sisley et aL, 1990, Sisley et aL, 1992, Prescher et aL,
1995). Amplification of 8q in conjunction with monosomy 3 correlates with reduced 
survival and is usually associated with a ciliary body location (Sisley et aL, 1997, 
Sisley et aL, 1992).
In some of the above studies (Kilic et aL, 2005, Aalto et aL, 2001), loss of Ip (region 
p36) was a predictor of an unfavourable outcome and was more frequent in large 
melanomas (Sisley et aL, 2000). In a study of 120 uveal melanomas, 89% of the 
metastasised tumours with loss of lp36 also had monosomy 3 (Kilic et aL, 2005); 
among other numerical changes in chromosomes 1,3, 6 and 8, only the concurrent 
loss of the short arm of chromosome 1 and all of chromosome 3 was an independent 
predictor of decreased disease-free survival (Kilic et aL, 2005).
The results observed by Kilic et al in their more recent study of 74 primary uveal 
melanomas (Kilic et aL, 2006) have also confirmed the findings of other studies that 
stated that monosomy of chromosome 3 seems to be an early event, occurring before 
alterations of chromosome 8,1 and 6 (White et aL, 1998, Sisley et aL, 1997, Prescher 
et aL, 1996). In some of the above studies changes in chromosome 6 were present as 
losses of 6q and gains of 6p (White et aL, 1998, Kilic et aL, 2006, Kilic et aL, 2005, 
Aalto et aL, 2001). Gain of 6p was associated with spindle cell type (Kilic et aL,
2005) and was reported to be higher (but not reaching statistical significance) in non- 
metastasising primary tumours (Aalto et aL, 2001). Conversely, losses of 6q were 
significantly higher in the metastasising group compared with the non-metastasising 
tumours (Aalto et aL, 2001).
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Table 1.2Chromosomal changes in choroidal melanomas
CHROMOSOME ABNORMALITY REFERENCES
Chr. 1 Ip loss K ilic et al., 2006; Aalto et al., 2001 
Sisley et a i ,  1990
Iq gain K ilic et al., 2006; Aalto et al., 2001
Chr2 2p loss K ilic et al., 2006
C hr 2 gain Gordon ef a/., 1994
2q gain Kilic et al., 2006
Chr 3 3p loss K ilic et a l ,  2006; Aalto et al., 2001  
Horsman & W hite, 1993 
Vajdic et al., 2003
Presher ût/., 1990; Gordon et al., 1994  
Speicher et al., 1994; Sisley et a l ,  2000
3q loss The same as for 3 p loss
Chr 6 6p gain Kilic et al., 2006; Aalto et al., 2001 
Sisley  et aL, 1990; Speicher et al., 1994  
Fresher et a i ,  1990; Vajdic et a l ,  2003
6q loss K ilic et aL, 2006; Aalto et aL, 2001  
Sisley  et al,. 1990; Speicher et aL, 1994 
Fresher et aL, 1990; Vajdic et aL, 2003  
Horsman & W hite, 1993
6p loss K ilic et aL, 2006
Clir7 7q gain K ilic et aL, 2006; S isley  et al., 1990  
Gordon et al, 1994
Chr 8 8p gain K ilic et aL, 2006; Aalto et aL, 2001
8p loss K ilic et aL, 2006
8q gain K ilic et al., 2006; Aalto et aL, 2001  
Horsman & W hite, 1993 
Vajdic etaL,  2003
Fresher éf a/., 1990; Speicher et aL, 1994
Chr 9 9p gain Kilic et aL, 2006; Gordon et a l ,  1994
9p loss Kilic et al., 2006; Speicher et al., 1994
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Table 1.2 continued
CHROMOSOME ABNORMALITY REFERENCE
Chr 10 lOp loss Vajdic et aL, 2003
lOq loss Vajdic et aL, 2003
Chr 11 l lq  gain K ilic et aL, 2006
Chr 13 13q loss Aalto et aL, 2001
13 q gain Gordon et al., 1994
Chr 15 15p loss K ilic et aL, 2006
15q loss K ilic et aL, 2006
Chr 16 16q loss K ilic et aL, 2006
Vajdic et aL, 2003
16p gain Aalto et aL, 2001
Chr 20 20q gain Aalto et aL, 2001
Chr 21 21p loss K ilic et al., 2006
Chr 22 22p loss Kilic et al., 2006
22q gain Aalto et aL, 2001
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Loss of chromosome 3 may also be associated with isochromosome formation of Iq, 
6p,8q,16p,20q and 22q but the mechanism is not known (Aalto et aL, 2001) and the 
relationship with prognosis remains unclear. It is also apparent from the different 
studies that the chromosomal changes in uveal melanoma are also distinct from those 
associated with cutaneous melanoma. For example, involvement of chromosome 6 is 
less common in uveal melanoma, whereas loss of chromosome 3 is infrequent in 
cutaneous melanoma (Horsman and White, 1993).
The association of monosomy 3 with histopathological parameters has been the 
subject of several investigations. Some studies have shown a correlation with cell 
type (specifically the presence of epithelioid cells) (White et aL, 1996, Schoies et aL, 
2003, Onken et aL, 2004, Kilic et aL, 2006). In addition, Scholes et al and Kilic et al 
found a correlation between monosomy 3 and intratumoural vascular loops, large 
tumour size and ciliary body involvement (Scholes et aL, 2003, Kilic et aL, 2006). 
However other studies did not report any significant association between 
histopathological parameters such as large size tumours (Sisley et aL, 1997) or 
vascular loops and the presence of epithelioid cells (Sisley et aL, 1997, Prescher et 
aL, 1996). These differences between studies may have arisen because of differences 
in the study populations.
The presence of monosomy 3 in metastasising uveal melanoma suggests a 
requirement for inactivation of multiple tumour suppressor genes (TSGs) located on 
both the short and long arms of chromosome 3 (White et aL, 1998, Prescher et aL,
1996). Previous studies have shown that in the majority of cases chromosome 3 loss 
of heterozygosity involves an entire chromosome homologue but in a small number
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of tumours only regional losses on chromosome 3 are identified (Tsechentscher et 
aL, 2001, Prescher et aL, 1996, Sisley et aL, 1997, White et aL, 1998, Scholes et aL, 
2001, Speicher et aL, 1994). Tschentscher et al studied 333 uveal melanomas and 
found partial deletions in 15 tumours, suggesting that TSGs might be the target of the 
deletions (Tsechentscher et aL, 2001). In this study 8 tumours had a paitial deletion 
of the long arm at 3q24-q26 and in 5 tumours the partial deletion was in the short 
arm at 3p25. Scholes et al tried to identify tumour-suppressor loci that may 
contribute to the pathogenesis of uveal melanoma (Scholes et aL, 2001). 
Microsatellite analysis were undertaken and their data support a role for 
retinoblastoma (RB) loci inactivation but also raise the possibility of the involvement 
of additional loci close to RB and p 16/cyclin-dependent kinase inhibitor 2 
(CDKN2A) (Scholes et aL, 2001). However none of the major tumour suppressor 
genes, including RB, seem to be mutated in uveal melanomas with any significant 
frequency, as evidenced by the normal expression of the RB protein in most of these 
tumours (Harbour, 2006).
Gene expression profiling studies have shown that uveal melanomas with and 
without monosomy 3 represent two distinct entities suggesting that they were not 
recognised before because they are not distinguishable by clinicopathological 
features (Tsechentscher et aL, 2003). Further gene expression profiling studies by 
Onken et al defined two classes of uveal melanoma (class 1 low-grade and class 2 
high-grade) and has found an association between class 2 and epithelioid cells and 
class 1 and spindle cells (Onken et aL, 2004). Genes that discriminate class 1 from 
class 2 include clusters of down-regulated genes on chiomosome 3 and up-regulated 
genes on chromosome 8q (Onken et oL, 2004) but no specific cancer genes have
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been linked to these loci (Harbour, 2006). It is still to be recognised whether class 1 
tumours evolve into class 2 tumours or whether the two classes develop along 
distinct pathways (Harbour, 2006).
Methods of assessment of chromosomal abnormalities
The techniques used for cytogenetic analysis of uveal melanoma include standard 
cytogenetics (Horsman and White, 1993, Sisley et aL, 1990), comparative genomic 
hybridisation (CGH) (Aalto et aL, 2001, Tsechentscher et aL, 2001), microsatellite 
analysis (Scholes et aL, 2001, Scholes et aL, 2003, Parrella et aL, 1999) and FISH 
(McNamara et aL, 1997, Naus et aL, 2002, Patel et aL, 2001).
In standard cytogenetics, fresh tissue is required and disaggregated tumour cells are 
cultured and chromosomes analysed in metaphase. However the cells which grow in 
culture may not be representative of the total tumour population (Speicher et aL, 
1994). Comparative genomic hybridisation and PCR-based microsatellite analysis 
have been undertaken on both fresh (Scholes et aL, 2001, Scholes et aL, 2003) and 
archival paraffin-embedded tissue (Parrella et aL, 1999). Both these techniques 
involve the extraction of DNA from the tissue samples. In CGH differentially 
labelled tumour and normal DNA samples are simultaneously hybridised to normal 
metaphase chromosomes. Regions of gains or losses within the tumour DNA can be 
identified by an increased or decreased colour ratio of the two fluorochromes used 
for the detection of hybridised DNA sequences along these reference chromosomes.
In microsatellite analysis paired primers are used to amplify microsatellite markers 
on chromosomes of interest. Both these techniques are performed using DNA
44
isolated directly from many tumour cells without culture and theoretically should 
more accurately represent the tumour cell population in vivo. However tissue 
samples can be contaminated with non-tumour DNA that may be amplified during 
PCR.
FISH has been used to assess cytogenetic abnormalities in uveal melanomas 
(McNamara et al., 1997, Naus et aL, 2002, Patel et aL, 2001) and by utilising 
different fluorochromes several chromosomes or chromosomal regions can be 
assessed simultaneously. The studies described however have utilised only fresh 
tissue and stained slides prepared from disaggregated tumour cells. FISH analysis for
other chromosome regions has been performed on tissue sections of choroidal 
melanoma (Walker et aL, 2002) but in the study by Patel et al. (Patel et aL, 2001) the 
authors commented that gluteraldehyde fixed tissue is not suitable for FISH analysis.
Using these techniques for cytogenetic analysis, there is also the potential risk of 
unknowingly examining non-representative tumour populations because these 
methods do not maintain tissue morphology. Therefore, techniques where tissue 
morphology is maintained would be advantageous. In addition techniques which 
could be applied to paraffin embedded tissue would allow studies to be undertaken 
on archival material with longterm follow up.
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Chromosome in situ hybridisation (GISH)
In situ hybridisation (ISH) is a technique that allows identification of specific nucleic 
acid sequences within individual cells, either in tissue sections or in whole cell 
preparations. It is based on the complementaiy binding of a nucleotide probe to a 
specific target sequence of DNA or RNA in the cell (McNicol and Farquharson,
1997). The added probe is labelled with a reporter molecule and sites of binding are 
visualized by their location. Initially, radioactive labelling limited the application to 
research areas. Fluorescent markers are the most commonly applied reporter 
molecules in diagnostic work (FISH techniques) but other signal-generating systems 
exist such as enzymes and metals. The major advantages of using enzyme-mediated 
detection systems in ISH techniques are the permanence of signal and the use of 
cheaper and simpler light microscopes in comparison to fluorescent microscopes. 
The availability of different systems will enable the simultaneous detection of 
different nucleic acid sequences, also generating a more permanent signal (Leitch et 
al., 1994). The use of labelled chromosome-specific DNA probes in combination 
with the ISH technique enables the detection of numerical and structural 
chromosome aberrations in both metaphase spreads and interphase nuclei (Poddighe 
et aL, 1992). This technique, chromosome in situ hybridisation, if applied to 
choroidal melanoma will offer several advantages over currently available 
techniques. Firstly, tissue morphology is maintained and this ensures that the nuclei 
assessed are indeed tumour cells. Secondly, it takes account of tumour heterogeneity 
and allows the correlation of genotype with phenotype. Finally, it will be possible to 
study archival tissue therefore providing adequate numbers for study and longterm 
follow up.
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1.3 Diagnostic Modalities
1.3.1 Ocular examination and colour photography
Ophthalmoscopic examination of choroidal melanoma by binocular indirect 
ophthalmoscopy almost always establishes the diagnosis. Colour photography is also 
indispensable for follow up of indeterminate melanocytic lesions and after 
conservative treatment of melanoma.
1.3.2 Fluorescein Angiography
“Double circulation” consisting of choroidal and tumour vessels that are leaky in late 
phases of a fluorescein fundus angiography is suggestive of uveal melanoma (Shields 
et aL, 1991) but the use of fluorescein angiography is limited since no 
pathognomonic pattern exists (Lederer and Edelstein, 2004).
1.3.3 Ultrasonography
Ultrasonography has greatly helped ophthalmologists in the management of 
choroidal melanomas and it is performed in almost all patients with choroidal 
masses. Ultrasound examination is particularly useful for measuring tumour 
dimensions when planning treatment and when assessing the response to treatment. 
With A-scan, a melanoma shows a high initial spike and low to medium reflectivity 
with decreasing amplitude followed by a prominent spike corresponding to the
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sclera. B scan typically shows a choroidal mass with acoustic hollowness and 
choroidal excavation (Shields et aL, 1991).
1.3.4 Magnetic resonance imaging (MRI) and computerized 
tomography
MRI and computarized tomography are not performed routinely since these rarely 
provide information that is not obtained more conveniently using ultrasonography. 
However MRI is required for radiation treatment planning in some centers (Damato,
2006).
1.3.5 Biopsy
Choroidal melanoma can be accurately diagnosed without the use of invasive 
techniques in around 98% of cases (Bechrakis et aL, 2002). However for those 
tumours that can not be diagnosed clinically and where a therapeutic decision will be 
made depending on the diagnosis various intraocular biopsy methods have been 
proposed (Shields et aL, 1991). Intraoculai' biopsy is most commonly performed 
transvitreally by fine-needle aspiration (FNA) although the transscleral technique is 
still in use in some centers (Bechrakis et aL, 2002). However there has been some 
concern that FNA could induce tumour seeding along the needle tract (Karcioglu et 
aL, 1985) and that material obtained might not be representative of the entire tumour 
(Folberg et a l,  1985). Sen et aL have undertaken transretinal biopsy of choroidal 
tumours using a 25-gauge vitrector (Sen et aL, 2006). Although the study group was 
small (14 cases) this technique appears to provide a larger sample than FNA and it is 
a shorter procedure than 20-gauge biopsy. No adverse outcomes were identified in 
this small series of patients.
1.3.6 Cytogenetic Studies
At present, cytogenetic studies are carried out if a tumour sample is obtained for 
diagnostic reasons or after local resection or enucleation. In the future, the results of 
cytogenetic studies may influence treatment and as such it may be desirable to 
sample small tumours in order to prevent métastasés (Damato, 2006). Genetic 
tumour classification will also help to identify patients who might benefit from 
adjuvant therapy.
1.4 Treatment
The main objective of treatment in choroidal melanomas is to avoid the development 
of a painful and unsightly eye, either by enucleation or by eye-conserving therapies. 
Malignant choroidal melanomas were treated for decades by enucleation but sight 
conservative treatments have been encouraged since there is no convincing 
difference in survival between radical surgery of the eye and eye conserving 
therapies (Char et ah, 1988, Foulds et ah, 1987, Seddon et ah, 1990). Largest tumour 
diameter influences retention of the globe (Foulds et ah, 1987) and tumour height 
determines the type of radiation and dose in plaque brachytherapy treatments 
(Damato, 2004). However it is generally believed that intraocular melanoma has 
already disseminated at the time when treatment of the primary tumour is given.
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1.4.1 Enucleation
An earlier theory stated that enucleation at a very early stage was most likely to 
prevent métastasés particularly for small melanomas in order to prevent the initial 
dissemination of tumour cells (Zimmerman et al., 1980, Manschot and van 
Peperzeel, 1980). However, later it was suggested that surgical manipulation during 
enucleation disseminated tumour cells into the vascular system, thereby increasing 
melanoma-related mortality (Zimmerman and McLean, 1979). This hypothesis was 
based on the observation of the pattern of mortality which peaked at 2-3 years after 
enucleation and stabilised to the pre-enucleation level by the 7^  ^ year after 
enucleation and also on the assumption that 1% of patients with malignant melanoma 
would die each year. Thus, in order to prevent cellular dissemination and métastasés, 
various adjuvant treatments were proposed, such as pre-enucleation radiation, but
'!this did not improve survival (Char et al., 1988). This hypothesis was controversial.
Siegel et al. reanalysed the survival data appraised in the Zimmerman study and 
found no evidence to suggest that surgery promoted or accelerated the development 
of metastatic disease (Siegel et al., 1979). Other studies have also failed to show 
improvement in survival after enucleation (Augsburger et a l,  2004a, Foulds et al,
1987, Seddon et a l,  1990) and therefore in recent years, alternative treatments to 
enucleation have been used more frequently to manage posterior uveal melanoma, 
with the aim of preserving vision. These include radiotherapy, local resection and 
transpupillary thermotherapy (Shields et a l ,  1991). A non-intervention approach for 
small tumours was also adopted. Enucleation is however still required in some cases; 
for example, for small and medium-sized choroidal melanomas documented to be 
growing and invading the optic nerve, tumours too extensive at presentation or for
50
the relief of pain due to neovascular glaucoma, which is most common after 
brachytherapy of large tumours (Damato, 2004, Shields et al., 1991).
1.4.2 Eye conserving therapies 
Observation
It is common for small melanocytic lesions of the choroid to be observed without 
treatment until any growth is documented (COMS, 1997). Although it remains 
unclear whether treatment of small tumours prevents métastasés, it is important for 
the clinician to recognise those tumours at high risk for growth and treat eaily 
(Shields et al., 2002). The factors that predict aggressive behaviour of a small 
choroidal tumour include thickness greater than 2 mm, subretinal fluid, symptoms, 
orange pigment and margin at the optic disc (Shields et al., 2000). Observation only 
is also indicated for elderly or debilitated patients as long as the eye is comfortable 
(Damato, 2004).
Radiotherapy
Radiotherapy given either with episcleral radioactive plaques sutured to the sclera 
over the tumour (brachytherapy) or with accelerated protons or helium ions often 
saves functional vision in the eye with uveal melanoma particularly when the tumour 
is small (Gragoudas et al., 1987, Shields et al., 1991). Stereotactic radiotherapy has 
similar indications to proton beam radiotherapy and delivers fine beams of photons 
to the tumour from many directions (Damato, 2006).
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Radiotherapy induces widespread DNA damage, which kills many tumour cells and 
prevents surviving cells from proliferating (Hai'bour et al., 2003). Not all tumour 
cells are sterilised by irradiation and some cells may recover (Rousseau, 2004). The 
growth potential of such tumour cells is however unpredictable (Schilling et al.,
1997).
The radioactive sources more commonly used are cobalt^^, iodine^palladium^^^ or 
ruthenium^lodine^^^ and ruthenium^are more commonly used in North America 
and Europe, respectively (Finger, 1997). Ruthenium plaques which emit p radiation 
have a more limited range and are the first choice of therapy for choroidal tumours 
up to 5mm thick and not extending close to the optic disc (i.e.< 3 mm) whereas 
iodine plaques which emit gamma radiation can treat tumours up to 8-10mm thick 
(Damato, 2004). With plaque radiotherapy the aim is to deliver at least 80 Gy to the 
tumour apex (Shields et al., 1991).
Compared with brachytherapy, proton beam radiotherapy is more expensive, time 
consuming and more likely to cause discomfort. This form of treatment is usually 
reserved for small, posterior choroidal tumours less than 6 mm thick and extending 
close to the optic disc and for large choroidal tumours (tumours more than 5 mm 
thick), as an alternative to trans-scleral local resection (Damato, 2006). As with 
brachytherapy, local tumour recurrence after proton beam radiotherapy is associated 
with increased mortality but the explanation for this is still unclear (Egan et al.,
1998).
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Depending on the site and dose of radiotherapy complications of radiation 
retinopathy, cataract and neovascularisation can occur (Damato, 2006). These 
complications could potentially be treated by intraocular administration of steroids 
and antiangiogenic agents (Damato, 2006).
Phototherapy
Thermotherapy given through a dilated pupil (transpupillary thermotherapy-TTT) 
consists of the delivery of a long-duration, long-wavelength (810nm) diode laser 
through a large spot size (Oosterhuis et al., 1995). It has been shown to be an 
effective treatment for selected small choroidal melanomas and also for larger ones 
in combination with brachytherapy (Shields et al., 2002, De Potter et al., 1996). In 
transpupillary thermotherapy there is low lateral spread of heat into adjacent tissues; 
therefore it may be especially useful for tumours in the macular area and adjacent to 
the disc to retain central vision (Oosterhuis et at., 1995). However concerns have 
been raised regarding the long-term tumour control with primaiy TTT (Harbour et 
al., 2003, Shields et a l ,  2002) since this method does not seem to completely 
eradicate intrascleral tumour cells (Keunen et a l,  1999), that may be present in up to 
55.7% of uveal melanomas (COMS, 1998 a). Therefore, at present, the main role for 
TTT seems to be as an adjunct to plaque radiotherapy (Shields et a l,  2002).
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Local resection
The two techniques of local resection for choroidal melanomas include trans-scleral 
local resection and endoresection. Melanomas which meet the criteria for trans- 
scleral local resection can also be managed by radiotherapy in most cases; however 
relative indications for the former include tumours located more anteriorly, with a 
smaller base and a greater thickness (tumours exceeding 5-6 mm in thickness), since 
such tumours require a much higher radiation dose (Shields et al., 1991). Local 
resection is not commonly performed because it is difficult and requires careful 
patients selection due to the profound hypotensive anaesthesia necessary for this 
procedure. Trans-retinal resection or endoresection of choroidal melanoma remains 
controversial because of the risk of seeding tumour cells; endoresection can however 
be performed for juxtapapillary tumours up to 10mm in diameter if the patient 
requires good vision in the affected eye (Damato, 2004).
Orbital exenteration
Exenteration of the orbital contents has been considered an acceptable method to 
treat advanced cases of uveal melanomas with extraocular extension into the orbit 
(Shammas and Blodi, 1977). Due to improvement of diagnostic techniques and 
earlier recognition it has become uncommon for patients to initially present with 
extensive extraocular involvement requiring orbital exenteration. (Shields et ai,  
1991). Although there is justification for orbital exenteration in such cases, 
controversy continues regarding both the indications for its use and its success in 
improving patient prognosis. Shammas and Blodi (Shammas and Blodi, 1977) found
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that early exenteration for extraocular extension was curative, with 87% of the 
patients surviving 5 years or more but Kersten et al. reported that this form of 
treatment was palliative and prognosis was not altered in those who had an 
exenteration (Kersten et al., 1985). Data based on mathematical studies of tumour 
doubling time and related métastasés also suggest that métastasés of choroidal 
melanoma can potentially occur early in the course of the disease, before treatment 
for primary tumour is given (Eskelin et a l ,  2000).
1.5 Metastatic disease
1.5.1 Prediction and mortality rates
The prognosis for uveal melanoma is difficult to predict and despite advances in 
diagnosis and management of uveal melanoma, the overall mortality remains high 
(50%) due to a propensity for the tumour to metastasise to the liver (Diener-West et 
al., 1992, Mooy and De Jong, 1996), According to the COMS Group, the métastasés 
develop in the liver in 93% of cases (COMS, 2001). Despite treatment advances the 
survival rate for choroidal melanoma still remains 72% at 5 years, 60% at 10 years 
and 55% at 15 years (Rousseau, 2004). The median survival time for a patient with 
liver métastasés is only 7 months (Kath et al., 1993). The peak mortality from 
metastatic disease occurs within 3 years of diagnosis but the clinical course is 
unpredictable since métastasés may present up to 36 years later (McLean et al., 1982, 
Newton, 1965).
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1.5.2 Screening for métastasés
The liver is involved in up to 95% of patients with metastatic disease, with about 
50% of patients also developing extrahepatic métastasés, most often in the lungs, 
bone, skin and brain (Eskelin et al., 1999). The reason why the liver is almost always 
involved is unknown. Foss suggested that it could be explained in terms of 
expression of adhesion molecules but the liver is most frequently involved by many 
malignancies (Foss, 1996). Lindegaard et al. found métastasés to the central nervous 
system (CNS), kidney, heart, or adrenal glands was only in patients with optic nerve 
invasion, suggesting that this feature may result in a different metastatic pattern 
(Lindegaard et al., 2006). Since there are no lymphatics within the eye, involvement 
of regional nodes is very rare, occurring only when there is extraocular spread.
To date, the procedures and time intervals which constitute an optimal follow up 
have not been established and differences exist between different centres (Hicks et 
al., 1998, Eskelin et al, 2000). Although it is accepted that biochemical liver 
function tests are insensitive (Diener-West et al., 2004), Eskelin et al. have shown 
that liver ultrasonography and biochemical liver function tests can detect métastasés 
before the onset of symptoms in about 59 % of patients when performed annually 
and in more than 95% if performed every 6 months (Eskelin et al., 1999). However 
Hicks et al. concluded that all single liver function tests had poor sensitivity for 
metastatic disease and recommended routine liver ultrasonography at both 
presentation and follow up (Hicks et al., 1998). Another area of common tumour 
involvement is the lungs and in one series (Kath et a l,  1993) the percentage of 
pulmonary involvement was 46%. These authors suggested that a chest radiograph 
should be performed at least every 6 months. However it has also been suggested that
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chest radiography is of no additional value since patients with pulmonary métastasés 
usually already have hepatic métastasés (Damato, 2004).
1.5.3 Treatment of systemic métastasés 
Regimens/trials for chemotherapy
Currently there is no effective treatment for metastatic uveal melanoma. Vaiious 
chemotherapeutic regimes have failed to show significant survival benefit in patients 
with extensive disease (Kath et al., 1993). A review of the M.D. Anderson Cancer 
Center experience compared the results of different modalities available to treat liver 
métastasés including systemic chemotherapies, hepatic intra-arterial chemotherapies 
and chemoembolisation of liver métastasés (Bedikian et al., 1995). Of the thiee 
modalities of therapy only chemoembolisation using cisplatin-based regimens 
produced a meaningful response rate. However toxicity and complication rates with 
these cisplatin regimens are high and therefore they have not become a standard 
treatment (Rousseau, 2004). Pyrhonen et al. had a modest response in treating 
metastatic uveal melanoma in hepatic and extrahepatic sites with a combination of 
bleomycin, vincristine, lomustine and dacarbazine (the BOLD regimen) plus 
interferon-a regimen (Pyrhonen et al., 2002). Laboratory tests suggest that 
gemcitabine and treosulphan might be effective but clinical studies are necessary 
(Neale et al., 2001).
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Imm unotherapy
Immunotherapy with interleukin-2 or interferon-a and -y has not shown consistent 
activity in metastatic uveal melanoma. In contrast, in vitro data has shown an effect 
of interferon-a and -y on primary human uveal melanoma cell lines (Wdll et a l,
1999).
Gene therapy
Studies in mice were undertaken by Alizadeh et al to determine whether transfer of 
interferon- beta-(IFN-(3) gene will protect against liver métastasés arising from 
intraocular melanomas (Alizadeh et al., 2003). The results suggested gene transfer as 
a possible strategy for controlling liver métastasés arising from intraocular 
melanomas. This study was based on the knowledge that adenovirus vectors have a 
predilection for transferring genes to the liver after IV injection, also that IFN-p is a 
potent activator of natural killer (NK) cells and that the liver has the highest 
concentration of NK cells in the body (Alizadeh et al., 2003).
Ma et al. also developed a mouse model to test whether plasminogen activator 
inhibitor type I (PAI-1) affected the development of liver métastasés (Ma et al.,
1997). Plasminogen activator (PA) is known to facilitate tumour métastasés by 
promoting invasion of tissue barriers but PAI-1 can inhibit PA bound to the cellular 
receptor and also block tumour cell binding to the extracellular matrix. In these 
studies intraocular injection of adenovirus expressing PAI-1 resulted in reduction of 
liver métastasés by 50% (Ma et al., 1997). These results support the disruption of PA
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function through gene transfer as a therapeutic strategy for preventing métastasés and 
prolonging host survival.
Surgery for métastasés
Surgical excision of an isolated hepatic métastasés can sometimes prolong life 
significantly (Fournier et aL, 1984). Other results suggest that the combination of 
chemotherapy and surgery may have useful activity. For example, Rajpaland et al. 
treated 11 patients who developed metastatic disease with chemotherapy and surgery 
and 9 remained tumour-free for at least 12 years (Rajpal et al., 1983). In a 
prospective study, Salmon et al. showed that those patients in whom curative 
resection was possible, the mean survival was significantly better (22 months) than 
the overall survival of 9 months for patients who had biopsies or tumour reductions 
with partial surgery and chemotherapy (Salmon et al., 1998).
Targeted therapies
New prognostic factors/molecular targets, such as specific membrane receptor 
inhibitors are being evaluated to provide the biologic basis for the development of 
new treatments. In vitro assays have shown that treatment with IGF-IR blocking 
antibody reduces the expression of the receptor at the cell surface (All-Ericsson et 
al., 2002). In this study, All-Ericsson et al. investigated the immunohistochemical 
expression of IGF IR in 36 uveal melanomas and found a correlation between high 
levels of expression of IGF-IR and decreased survival rates. As shown in this study
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and in others (Girnita et al., 2000, Drieu et al., 1997, All-Ericsson et al., 2002), 
experimental treatment with a-IR3 (IGF-IR blocking antibody) or tunicamycin 
(inhibitor of IGF-IR N-linked glycosylation) diminishes the expression of the 
receptor at the cell surface and also decreases cell viability and DNA synthesis.
The proto-oncogene c-kit encodes a transmembrane receptor-type protein tyrosine 
kinase (kit) whose ligand is a stem cell factor (SCF, also known as steel factor, kit 
ligand, and mast cell growth factor) (Mouriaux et al., 2003). C-kit is expressed and is 
important for the development of normal cells such as cutaneous melanocytes, mast 
cells and hematopoietic stem cells but it has also been detected in a wide variety of 
human malignancies such as gastrointestinal stromal tumours and more recently in 
uveal melanomas, suggesting that growth and survival of uveal melanoma cells is 
dependent on c-kit activation (Mouriaux et al., 2003, All-Ericsson et al., 2004). 
Furthermore, the KIT pathway can be blocked with the tyrosine kinase inhibitor 
imatinib mesylate (ST1571); this was initially approved for the treatment of chronic 
myeloid leukaemia (Druker et al., 2001) but it has also been shown to be effective in 
KIT-positive gastrointestinal stromal tumours (van Oosterom et al., 2001). All- 
Ericsson et al. suggested that this drug could also have a possible therapeutic benefit 
in uveal melanoma through its inhibitory effects on c-kit phosphorylation and cell 
proliferation (All-Ericsson et al., 2004). Imatinib has also been suggested a potential 
treatment for patients with ocular melanoma expressing c-KIT (Fiorentini et al., 
2003).
Angiostatin is a degradation product of plasminogen and is produced in the presence 
of a primary tumour. It also inhibits the growth and development of métastasés
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although the exact mechanism remains uncertain (Apte et al., 2001). Apte et al. 
showed that uveal melanoma cell lines produced angiostatin in vitro and that 
removing a source of angiostatin by enucleating a melanoma-containing eye could 
exacerbate metastatic disease (Apte et al., 2001). Exogenous angiostatin may 
therefore have potential therapeutic implications in the management of patients with 
primary intraocular melanomas.
1.6 Counselling the Patient with a Choroidal Melanoma
Patients with choroidal melanomas, even if the eye and vision are maintained often 
suffer a lot of distress because of the unpredictable overall outcome. As none of the 
different treatments available offer a survival advantage, the treatment of choice 
should be guided by the effects on quality of life (Foss et al., 2000). This fact should 
be highlighted to all new patients to avoid unnecessary distress if later on they 
develop metastatic disease. Therefore, the main aim in the management of patients is 
to restore quality of life. To determine whether quality of life differs between 
patients with choroidal melanoma treated by enucleation and those treated by 
radiation therapy, Cruickshanks et al. studied 147 patients (65 treated by enucleation 
and 82 treated by radiation therapy) and concluded that treatment for choroidal 
melanoma does not seem to be associated with a large difference in quality of life in 
long-term follow up (Cruickshanks et al., 1999).
A modified questionnaire described by Foss et al (Foss et al., 2000) known as 
MOOD (measure of outcome in ocular disease) includes a 21 item questionnaire 
which assesses the patient’s assessment in terms of visual function and the impact of 
treatment. The MOOD proved to be well accepted by the patients and its validity was
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supported by high correlations between the vision and impact scales. MOOD total 
scores were significantly higher for patients who reported being very satisfied 
compared with those who were not. Such tools may help to identify problems 
encountered after treatment of choroidal melanoma and in guiding follow-up.
Cytogenetic studies may be an important additional tool for counselling these 
patients. Although patients with melanoma containing two copies of chromosome 3 
have a better prognosis for survival some may still die from métastasés. By 
identifying tumours that are monosomie for chromosome 3 patients at high risk of 
metastases-related death can be identified for close follow up. Patients with clinical 
metastatic disease unresponsive to treatment may prefer to be informed of their poor 
prognosis so that they can make appropriate arrangements while they are well 
(Schoies et a l, 2003).
1.7 Aims and Objectives
The aim of my work is to develop the CISH technique to identify monosomy 3 in 
archival tissue. To date the majority of studies have been prospective and the ability 
to study archival tissue has the advantage of large specimen numbers and long follow 
up. A further aim is to compare the efficiency of the CISH technique with FISH 
when assessing monosomy 3 in archival tissue sections of choroidal melanomas. 
Having developed the technique for archival tissue a further aim is to assess the time 
until death in patients with and without monosomy 3. The final aim will be to assess 
whether monosomy 3 corresponds with morphological subclones.
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2 IDENTIFICATION OF MONOSOMY 3 IN 
CHOROIDAL MELANOMA BY 
CHROMOSOME IN SITU 
HYBRIDISATION
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2.1 Background
The majority of cytogenetic studies on uveal melanoma have required fresh tissue for 
short term culture, fluorescence in situ hybridisation or DNA extraction. DNA may 
also be extracted from paraffin embedded tissue for analysis (Aalto et al., 2001, 
Schoies et al., 2001, Sisley et al., 2000, White et al., 1998, Naus et al., 2002, Patel et 
al., 2001, S choies et al., 2003, Prescher et a l, 1996, Sisley et al., 1997). None of the 
techniques described, however has identified the presence or absence of monosomy 3 
within tissue sections.
In this study I have used the alternative approach of interphase cytogenetics where 
the use of chromosome-specific DNA probes in combination with the ISH technique 
allows the detection of numerical and structural chromosome aberrations in both 
metaphase and interphase nuclei (Poddighe et al., 1992).
2.2 Specific Objective
To develop the technique of CISH to assess chromosome 3 copy number in tissue 
sections from formalin or gluteraldehyde fixed archival choroidal melanomas.
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2.3 Materials and Methods
2.3.1 Study population
Fifty six archival specimens of choroidal malignant melanoma were obtained from 
the Western Infirmary Pathology files. The specimens included local resection and 
enucleation specimens; surgery was performed between 1973 and 1992. All tissues 
had been previously fixed in gluteraldehyde or formalin and embedded in paraffin 
wax. Twelve of the 56 cases had been formalin fixed (FF). The remaining tumours 
had all been fixed in gluteraldehyde (GF). The FF and GF specimens were of similar 
ages. In 14 enucleation specimens (3 FF and 11 GF) normal retina was used as an 
internal control. In addition, eight cases of normal human skin (all gluteraldehyde 
fixed) were included as an external control. Full ethical approval in accordance with 
local policy was obtained for the use of these tissue samples.
2.3.2 Chromosome in situ hybridisation 
Pretreatment of Slides
Sections, 4pm thick, were mounted on aminopropyltriethoxysilane coated glass 
slides. Before use, the slides were baked at 65°C for at least 4 hours. The tissue 
sections were de waxed in 100% xylene and rehydrated in graded ethanol to water. 
For heavily pigmented tumours, the slides after being dewaxed were placed in 5% 
hydrogen peroxide in TBS (tris buffered saline) overnight at room temperature and 
then washed in water. All sections were microwaved in Tris-EDTA (4.5mM Tris, 
ImM EDTA, pH8) at full pressure for 5 min. After rapid cooling the sections were
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then digested with pepsin (0.4% pepsin in 0.2M hydrochloric acid) for 30 min at 
37°C and post-fixed for 10 min in tissue fixative (Streck Laboratories Inc., Omaha, 
NE, USA). Finally, sections were dehydrated in 100% ethanol and air-dried.
DNA Probes
In situ hybridisation
The probe in the hybridisation mix and DNA in the tissue sections were co-denatured 
together using the Omnislide modular system (ThermoLife Sciences, Hampshire, 
UK) at 80°C for 5 min. The tissue sections were then incubated with the probe at 
37°C overnight. After hybridisation, slides were washed twice in 2 x SSC at room 
temperature for 5 min and then in IxSSC at 70°C for 5 min. Prior to
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Chromosome-specific repetitive sequence probes for chromosome 3 (D3Z1) and 
chromosome 18 (D18Z1) were purchased from Q-Bio gene (Illkirch, France). Both 
are alpha satellite chromosomes which specifically hybridises to the highly repeated 
alphoid DNA located at the centromere of human chromosomes 3 and 18. 
Chromosome 18 was used as a control chromosome, as it appears to rarely show 
abnormalities in uveal melanoma. Both commercial probes were ready labelled with 
digoxigenin. Probes were diluted 1:10 in a hybridisation mix consisting of 70% 
formamide, two times the standard concentration of standard saline citrate (SSC) 
(IxSSC is 0.15M sodium chloride and 0.015M sodium citrate, pH7), 500pg/ml 
salmon sperm DNA, and 10% dextran sulphate.
immunohistochemical detection of hybridised probe the slides were washed in 
4xSSCT (4xSSC, 0.05% Tween-20) and blocked for 30 min at room temperature in 4 
X  SSCT, 10% blocking reagent (Roche, USA). The slides were then incubated with 
anti-digoxigenin alkaline phosphatase (AP) Fab fragments (Roche, USA) 1:500 
dilution in 4xSSCT, 10% blocking reagent for 30 min at room temperature. Slides 
were washed in 4xSSCT for 5min, and then rinsed in distilled water. The slides were 
then incubated in NBT/BCIP solution (0.4mM nitroblue-tetrazolium (NBT), 0.38mM 
5-bromo-4chloro-3-indolylphosphate (BCIP), 1.25M levamisole in lOOmM HCl 
pH9.5, lOOmM NaCl, 50mM magnesium chloride) overnight. The sections were 
rinsed in tap water and counterstained with haematoxylin. Sites of binding were 
identified as blue-black dots.
Quantification of hybridisation signals
Chromosome-specific centromeric probes were hybridised to sections of choroidal 
melanoma. In order to obtain control values, centromeric copy numbers for the 2 
chromosomes were assessed using retina where present in the tissue sections and 
separate sections of normal skin. The evaluation and interpretation of ISH signals 
were carried out as previously described (Murphy et al., 1995, Hopman et ah, 1992). 
Firstly, tissue sections were examined by light microscopy using an oil immersion 
lens (magnification x 1000) and an eyepiece graticule to prevent recounting of 
nuclei. Overlapping nuclei and minor hybridisation signals were not analysed and 
only nuclei with the histological appearance of tumour cells were evaluated. Poor 
quality hybridisations were excluded. For each section the number of signal spots per
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nucleus was recorded for 200 nuclei and the assessor was masked for the outcome of 
the patient.
The hybridisation data were analysed in two ways to assess the degree of 
chromosome imbalance for each sample and each chromosome. Firstly, the 
chromosome index (Cl), which gives an average chromosome copy number, was 
calculated by dividing the total number of hybridisation spots counted by the total 
number of nuclei counted (Dhingra et a l, 1994). CIs are shown in figure 2.1. For 
chromosome 3 the mean Cl for retina and skin was 1.65 and 1.51 respectively. For 
chromosome 18 the mean Cl for retina and skin was 1.63 and 1.50. A tumour was 
defined as monosomie for chromosome 3 if its Cl was less than 3 standard deviations 
(3SD) from the mean {Le. less than 1.37) (Russel et a l, 1999).
The second method used to identify monosomy was the signal distribution (SD), 
which can potentially detect relatively small populations with chromosomal 
numerical imbalances. To define the signal distribution the percentage of the nuclei 
counted with one, two or more than two hybridisation sites was calculated. A tumour 
was described as monosomie for chromosome 3 if the percentage of nuclei with one 
hybridisation site was greater than 60% of the nuclei counted (Russel et a l, 1999).
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Figure 2.1 Chromosome index for chromosome 3 and 18
Scatter gram showing distribution of chromosome index (Cl) for chromosome 3 (A) and 18 
(B) in skin (solid diamond), retina (solid square), malignant melanoma (M, solid triangle); 
formalin fixed (FF, open circle), gluteraldehyde fixed (GF, open square). The lines denote die 
mean Cl (thick solid line), SD3 (thin solid line) or 2.58D (broken line) for retina. Values 
falling 3SD below the mean were classified as cliromosome loss.
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The criteria for both signal distribution and Cl were based on published estimates 
and previous experience of the technique and take into account nuclear truncation 
(Murphy et al., 1995, Hopman et at., 1992, Dhingra et aL, 1994). Nuclear truncation 
is an important aspect of interphase cytogenetic analysis since the way the section is 
cut will influence CL Hence, the chromosomal content of the nuclei included in the 
section will increase as a section thickness increases but as demonstrated before Cl is 
not significantly influenced by a change in section thickness from 4 to 8 pm. 
Tumours had to show chromosome loss by both Cl and signal distribution to be 
regarded as monosomie.
2.3.3 Statistical anaiysis
Differences in chromosomal indices between tumour and retina, GF and FF cases 
and older and newer tissues were compared using the two-sided Mann-Whitney test 
with a priori level of statistical significance set at p<0.05.
2.4 Results
2.4.1 In situ hybridisation
In situ hybridisation for chromosome 3 and 18 was successfully performed on 52 
choroidal melanomas. Four cases were excluded because of heavy tumour 
pigmentation and large areas of necrosis. There was no apparent visual difference in 
hybridisation reactions in FF tumours when compared with GF tumours. Examples
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of choroidal melanomas and normal retina hybridised with chromosome 3 and 18 are 
shown in figure 2.2.
2.4.2 Assessment of chromosome index
The Cl for chromosome 3 and 18 in choroidal melanoma and controls is shown in 
figure 2.1. There was no significant difference between the Cl for FF tissues when 
compared with the corresponding GF tissues. There was no significant differences 
between the Cl for tumours removed more than 20 years ago when compared with 
those removed less than 10 years ago. For choroidal tumours the CIs for 
chromosome 18 were not significantly different compared with that of normal retina 
and all lay within 2.75 standard deviations of the mean Cl for normal retina. For 15 
tumours the CIs for chromosome 3 were significantly different compared with 
normal retina (p=0.0013) and had a Cl more than 3 standard deviations from the 
mean. For the rest of the tumours the CIs for chromosome 3 were not significantly 
different compared with that of normal retina and all lay within 2 standard deviations 
of the mean.
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Figure 2.1 Chromosome in situ hybridisation.
A: Gluteraldehyde fixed normal retina, hybridised with chrom osom e 18, show ing  
two copies (double arrow) in m ost cells o f  the outer nuclear layer (ONL). The 
photoreceptors (pr) are towards the bottom o f  the picture, B: Gluteraldehyde fixed, 
m etastasising epithelioid (e) melanoma, hybridised with chrom osom e 18, show ing  
two copies (double arrow) in most cells. C: Formalin fixed, non-m etastasising  
epithelioid (e) melanom a, hybridised with chrom osom e 3, show ing two copies  
(double arrow) in m ost cells. D: Gluteraldehyde fixed, m etastasising spindle (s) 
melanoma with moderate pigmentation (p), hybridised with chrom osom e 3, showing  
one copy in m ost cells (single arrow) (m agnification x 1000)
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2.4.3 Assessment of signal distribution
For chromosome 18 the mean signal distribution for 2 or more hybridisation sites per 
nucleus was 64% for retina, 62% for skin and 57.5% for the choroidal tumours (FF 
57%; GF 58%). Therefore, by SD all the samples were balanced for chromosome 18. 
For chromosome 3 the mean signal distribution for 2 or more hybridisation sites per 
nucleus was 63% for retina, 54% for skin and 43% for the choroidal tumours (FF 
41.5%; GF 44%). By SD all the cases of normal retina and skin were balanced for 
chromosome 3. However by SD 15 cases of choroidal melanoma had greater than 
60% of nuclei with only one hybridisation site and were therefore defined as 
monosomie for chromosome 3 by this parameter (see table 2.1).
2.4.4 Assessment of monosomy 3
Tumours had to show chromosome loss by both Cl and signal distribution to be 
regarded as monosomie and therefore the data for Cl and SD were combined to 
assess monosomy 3. The results are sunamarised in table 2.2. Using both criteria 15 
of the 52 cases of choroidal melanoma were defined as monosomie for chromosome 
3. In all cases both pai ameters agreed and there were no cases where either the Cl or 
SD indicated monosomy but the other parameter did not.
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Chr3 No of cases with over 40,50, 60 or 70% of tumonr cell nnclei containing only
one hybridisation site
40% 50% 60% 70%
Skin, n=8 8 8 1 0
Retina, n=14 6 0 0 0
MeIanomas,n=52 45 25 15 14
FF, n=12 11 8 6 5
GF, n=40 34 17 9 9
FF, formalin fixed; GF, glutaraldehyde fixed
Table 2.1 Signal distribution for chromosome 3 showing the 
percentage of nuclei with only one hybridisation site
Chromosome 3 Chromosome 18
Loss Balanced Loss Balanced
Melanomas, n=52 15 37 0 52
Table 2.2 Tumours showing evidence of chromosomal changes by 
signal distribution and chromosome index.
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2.5 Discussion
This is the first study in which interphase cytogenetics has been applied to define the 
presence or absence of monosomy 3 in tissue sections of paraffin-embedded 
choroidal melanomas. The main advantages of CISH, used in this study, over other 
techniques are that it allows the direct assessment of chromosomal gains and losses 
in interphase and metaphase nuclei within a tissue section. This ensures that the 
nuclei assessed aie indeed tumour cells and that the chromosomal changes within the 
tumour cells can be directly compared with adjacent normal tissue. Cytogenetic 
studies on archival tumour specimens are important because of the availability of 
large series of fixed tumours that permit retrospective study of malignant 
progression, correlation with long clinical follow up and analysis of rare tumours. 
CISH was performed on archival tissue that was either formalin or gluteraldehyde 
fixed and I have successfully performed CISH on gluteraldehyde fixed tissue 
samples up to 30 years old.
In my laboratory CISH has previously been used to assess chromosomal gains and 
losses in other formalin fixed tumours such as adrenocortical tumours (Russel et al., 
1999). In these tissues good hybridisation signals could be obtained when slides were 
simply pre-digested with pepsin for up to one hour. This method of tissue preparation 
worked for formalin fixed choroidal melanomas but signal could not be obtained 
with gluteraldehyde fixed tissues. However by introducing a more rigorous pre­
treatment of microwaving under pressure in Tris-EDTA buffer, prior to pepsin 
digestion, good hybridisation signals were obtained. Interestingly, this additional step 
did not affect tissue preservation of formalin fixed cases and there were no 
significant differences between results obtained for Cl and SD between
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gluteraldehyde and formalin fixed cases. This pre-treatment was therefore adopted 
for all cases in this study. The criteria for scoring ISH signals, although previously 
established in other studies (Murphy et al., 1995, Hopman et al., 1991, Hopman et 
al., 1992, Emmerich et al., 1989), was checked by two observers using control 
sections and repeatedly assessing different fields. The numbers of nuclei per field 
were between 30 and 50 and 200 nuclei was an acceptable scoring criteria to identify 
the main chiomosomic fractions. Initially 20 slides were also independently assessed 
by my supervisor, Dr F. Roberts, and at any time during the study, when tumours 
presented with poorer staining intensity or more difficult morphology. At a later 
stage, and without knowledge of the initial result, I repeated the assessment for a 
random sample of 30 specimens. Inter- and intra- observer variation in counting was 
consistently less than 10%.
Using this technique monosomy 3 was identified in 15 of 52 cases (28.8%) of 
choroidal melanoma; the other 37 tumours were balanced for chromosome 3. The 52 
cases of choroidal melanoma were all balanced for chromosome 18. This 
chromosome was selected as a control as it rarely shows abnormalities in uveal 
melanoma. Using these criteria the results obtained for Cl and SD agreed in all cases 
of monosomy 3. The cut-off points were selected in accordance with this laboratory’s 
previous experience of the technique. A normal chromosome complement was 
defined as 3 standard deviations from the mean Cl. Other researchers have used a 
value of 2.58 standard deviations (Bulten et a i, 1998). If this value was applied to 
this study one case would not have been defined as monosomie by Cl. However for 
SD a strict cut off point of 60% of cells showing fewer than two hybridisation sites to 
define chromosomal loss was used compared with 40% or less used in other studies
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(Visscher et aL, 1996, Sneige et al., 1996). In Table 2.1 the number of cells with 40, 
50 and 70% of nuclei with only one hybridisation site is displayed. It is clear that in 
this study a cut off point of less than 60% would identify many normal tissues as 
monosomie. The identification of cells with only one hybridisation site in normal 
tissue reflects the effects of nuclear truncation and ultimately will be affected by the 
thickness of sections used, which may vaiy between studies. In this study 4 pm 
sections were used as this gave the best hybridisation signal. Using the higher cut off 
point of 70% one case would have been excluded. This is the same case that would 
have been excluded by defining a cut off point for Cl 2.58 standard deviations from 
the mean. This does not significantly alter the results but indicates that the cut off 
points may have to be re-assessed as more cases are studied.
The principal drawback of this technique is the effect of nuclear slicing on the 
number of signal spots, with the number of spots varying from zero to the actual 
copy number of the specific chromosome in that nucleus (nuclear slices in a thicker 
section will have a more complete chromosomal representation, whereas a smaller 
number will be present in a thinner section) (Dhingra et a l, 1992). However with 4 
pm thick sections as used in this study, the Cl does not change significantly 
compared to other thicknesses and also it gave the best hybridisation signal (Dhingra 
et al., 1994). A second drawback to this technique is that it is difficult to detect a 
change in copy number that affects only a small fraction of cells, missing for 
example the presence of monosomy. However Cl calculation and the distribution of 
signal spots prove to be complementary to each other in analysing ISH on tissue 
sections. The Cl gives an average chromosome copy number and is therefore better 
suited to describe clonal changes within a tumour whereas the analysis of signal
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distribution can potentially detect relatively small populations of cells with numerical 
imbalances in chromosomes (Dhingra et aL, 1994). Another confounding problem 
results from variations in hybridisation efficiency that can occur from one 
experiment to another. Strict adherence to the criteria for signal counting can further 
help eliminate false-positive signals caused by nonspecific binding (Hopman et aL, 
1988, Murphy et aL, 1995). Non-specific probe binding can also be excluded by the 
incorporation of appropriate controls. In enucleation specimens normal retina was 
used as an internal control. In addition, normal human skin was included as an 
external control.
In previous studies, other techniques rather than in situ hybridisation were used for 
the assessment of non-random chromosomal abnormalities such as standard 
cytogenetics (Sisley et aL, 1997, Sisley et aL, 1990, Horsman and White, 1993), 
CGH (Tsechentscher et aL, 2001, Prescher et aL, 1996, Aalto et aL, 2001), 
microsatellite analysis (Parrella et aL, 1999, Schoies et aL, 2001, Schoies et aL, 
2003) and FISH (McNamara et aL, 1997, Naus et aL, 2002, Patel et aL, 2001). The 
studies described however have utilised only fresh tissue and stained slides prepared 
from disaggregated tumour cells. CISH avoids the requirement for fresh tissue and 
the potential examination of non-representative tumour populations or non-tumour 
DNA. The preservation of tissue architecture during the process of CISH is the 
principal advantage of this method; chromosome heterogeneity can then be detected 
within the tumour with conelation of areas of specific chromosomic imbalances with 
the histological findings. This will help with the identification of subclones within a 
tumour and provide information on the role of monosomy 3 in tumour development.
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Direct comparisons are not possible between the results of interphase cytogenetic 
studies and techniques that involve DNA extraction such as microsatellite analysis 
and CGH (Ried, 1998). Unlike these techniques the main disadvantage of the CISH 
technique described is that fine mapping of changes cannot be achieved with alpha 
repeat centromeric probes. Microsatellite analysis and CGH have shown that in the 
majority of cases chromosome 3 loss of heterozygosity involves an entire 
chromosome homologue however in a small number of tumours regional losses on 
chromosome 3 have been identified and such regional losses cannot be detected with 
this technique as it stands (Schoies et al., 2001, Speicher et al., 1994). However 
probes for other chromosome regions are available and the technique could be 
adapted to detect regional losses. The technique could also be adapted to detect other 
chromosomes known to show gains or losses in uveal melanoma such as 8q (Sisley 
et al., 1997) and 6q (Aalto et aL, 2001), which are significantly associated with poor 
overall survival. It is also not possible to characterise specific tumour suppressor 
genes that may be involved. Nonetheless CISH represents a valuable additional 
technique that will allow the study of monosomy 3 in tissue sections allowing the 
correlation of genotype with phenotype. With CISH it is possible to screen a large 
archival series and define a group of tumours for more detailed study using 
alternative cytogenetic techniques. Finally the technique can easily be applied to 
routine pathology specimens without special treatment and could therefore identify 
high-risk patients who may benefit from close monitoring in whom effective 
adjuvant treatment might particularly be indicated.
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3 DETECTION OF MONOSOMY 3 IN 
ARCHIVAL CHOROIDAL MELANOMA 
USING FLUORESCENCE IN SITU 
HYBRIDISATION. A COMPARISON WITH 
CHROMOSOME IN SITU 
HYBRIDISATION
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3.1 Background
Fluorescence in situ hybridisation allows the interphase cytogenetic analysis of either 
fresh or archival tumour tissue. One of the main advantages of FISH compared with 
CISH is that multiple genetic changes can be examined in one preparation by the use 
of probes labelled with spectrally distinct fluorescent dyes (Leitch et aL, 1994). In 
patients with uveal melanoma FISH has been used on samples of disaggregated 
tumour cells to identify loss of chromosome 3 and extra copies of 8q. However these 
investigators have encountered several problems with the FISH technique including 
weak hybridisation signals in paraffin embedded tissue samples and masking of the 
hybridisation signal by autofluorescence. Patel et al have also commented that GF 
tissue is not suitable for FISH analysis (Patel et aL, 2001).
It is generally accepted that the key to successful FISH on archival tissue is the use 
of efficient pretreatments that will expose the target genes and allow the penetration 
of the probes (Chin et aL, 2003). The requirement for sufficiently rigorous 
pretreatments to expose target genes but without destroying tissue morphology may 
explain some of the difficulties encountered in previous studies.
3.2 Specific Objectives
1. To develop the technique of FISH to assess the presence of chromosome 3 in 
archival tissue sections of choroidal melanoma.
2. To compare the hybridisation signal obtained using FISH with that of CISH.
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3.3 Materials and Methods
3.3.1 Study population
Twenty archival specimens of choroidal malignant melanoma were selected from the 
original series. Cases that had been both successful and unsuccessful with CISH were 
considered. These included cases that had been unsuccessful due to heavy tumour 
pigmentation. The specimens included 7 local resections and 13 enucleations. 
Surgery was performed between 1974 and 2002. Three of the 20 cases had been FF. 
The remaining tumours had all been GF. In 13 enucleation specimens (ten GF and 
three FF normal retina was used as an internal control (as for CISH). Lymph node 
tissue was used as an external control.
3.3.2 Fluorescent in situ hybridisation
In developing the technique the effect of 2 different pre-treatments and both a direct 
and indirect treatment were assessed. The numbers subjected to each different stage 
are shown in Figure 3.1.
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20 Melanomas
CISH - 20 FISH - 20
Positive17 Negative3
Pretreatment
1
Pretreatment 2 on the 9 negative cases*
Direct16 Indirect 14 Direct9 Indirect 0
Positive
2
Formamide wash 12
Negative
12
Positive Negative7 9* Positive1 Negative8
Figure 3.1 A flow chart describing the different stages when attempting 
to apply FISH in paraffin wax embedded tissue sections.
( *  =  pretreatment 2 in negative results subgroup)
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Pretreatment of Slides
Sections of 4 jnm were pretreated by one of two different methods. Firstly all 20 
cases were pretreated as for CISH (pretreatment 1), as described in chapter 2. 
Briefly, the sections were pretreated by microwaving followed by digestion in pepsin 
(0.4% pepsin in 0.2M hydrochloric acid) for 30 minutes at 37°C. Nine of the original 
20 cases were also subjected to an alternative pre-treatment (pre-treatment 2) using 
the reagents and protocol in a commercial kit, kit II (Abbott, Berkshire, UK). The 
pretreatment solution in this kit consisted of sodium thiocyanate (NaSCN). The 
paraffin pretreatment reagent kit II had been used before in my laboratory on 
rhabdomyosarcoma and has been shown to be superior to the in-house method of 
microwaving under pressure. Briefly, paraffin-embedded tissues were dewaxed 
through xylene and alcohols and allowed to air dry. Slides underwent immersion in 
pre-treatment sodium thiocyanate (NaSCN) solution at 80°C for 10 minutes, washed 
in water then digestion in proteinase K in 0.2 M HCl at 37“C for 20 minutes, 
followed by fixation in 10% buffered formalin.
DNA Probes
Two different probes were assessed. The first probes assessed were biotin labelled 
centromeric probes to chromosomes 3 and 18 (Cambio, Cambridge UK). For these 
probes hybridisation sites were detected using streptovidin labelled with a 
fluorescent label, alexa fluor 594 (Invitrogen, Paisley UK). These indirect probes 
were applied separately to 14 cases (all GF) initially pretreated with pretreatment 1. 
The second probes assessed were alpha satellite probes to chromosome 3 (3 p ll.l-  
q l l . l )  and chromosome 18 (1 8 p ll .l-q l l .l)  both directly labelled with spectrum
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orange (Abbott). These probes were applied separately to 16 cases (13GF, 3FF) 
initially subjected to pre-treatment 1 (including 11 cases already assessed by the 
indirectly labelled probes) and to the subset of 9 cases (all GF) subjected to 
pretreatment 2 (Figure 3.1).
In situ Hybridisation
The appropriately diluted probe was applied to the prepared section using the 
Omnislide modular system (ThermoLife Sciences, Hampshire, UK) at 80°C for 5 
minutes and then allowed to hybridise overnight at 37°C. Post hybridisation washes 
for the indirectly labelled probes consisted of one five minute wash in 2xSSC at 37°C 
followed by two five minute washes in 60% formamide/2xSSC and two five minute 
washes in 2xSSC. For the directly labelled probes, the hybridisation washes were one 
two minute wash in 2xSSC/0.3% Igepal (Sigma) at 72°C followed by one minute 
wash in 2xSSC 0.1% Igepal at room temperature. In repeat experiments formamide 
washes were applied to reduce green background for the direct labelled probe in 12 
cases. These formamide washes consisted of three ten minute washes in 50% 
formamide/2xSSC at 42°C followed by one ten minute wash in 2xSSC at room 
temperature and a one five minute wash in 2xSSC/0.1% Igepal at room temperature. 
After the washes, every slide was then air dried in the dark and mounted using DAPI 
in vectashield mounting medium (Vector labs, Peterborough, UK). The coverslips 
were sealed with nail polish and the slides stored at 4°C prior to analysis. 
Hybridisation signals were assessed using an Olympus fluorescent microscope and 
images captured using image analysis software (Cytovision Applied Imaging, 
Newcastle, UK).
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Identification of hybridisation signal
The quality of FISH signals was analysed by assessing the relative fluorescent signal 
intensity of the probe and the amount of autofluorescence background. FISH was 
considered successful if strong hybridisation signals could be detected with a low 
level of background autofluorescence.
3.3.3 Chromosome in situ hybridisation
CISH was performed as previously described in chapter 2. Poor quality hybridisation 
signals were excluded.
3.4 Results
3.4.1 FISH for CHR 3 and CHR 18
Overall FISH was successful in 8 of 20 (40%) paraffin-embedded choroidal 
melanomas. Using the indirect biotin labelled probe FISH was successful in only 1 of 
14 cases with an additional case showing weak signal. The successful case was GF. 
Using the directly labelled probe following pre-treatment 1, seven of the 16 
specimens showed good hybridisation signal. Of the 11 cases previously assessed 
using the indirect probe 4 cases had a strong signal, only two of which had 
previously shown signal (one strong, one weak). After the pretreatment 2 was 
applied to the remaining 9 negative cases only one case showed a useful signal with 
the direct probe. Formamide washes did not reduce background signal.
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In the cases with good hybridisation signal, there was no significant difference 
between the signal for FF tissues when compared with the corresponding GF tissues 
(figure 3.2). Out of these successful cases, it would have been possible to count at 
least 100 cells. For the internal controls only one case showed good signal in the 
retina (figure 3.3) but the tumour in this case did not show any signal. Detectable 
signal was observed in the lymph node in all cases.
3.4.2 CISH FOR CHR 3 and CHR 18
In situ hybridisation for chromosome 3 and 18 was successfully performed on 17 of 
the 20 choroidal melanomas. Three cases were excluded because of heavy tumour 
pigmentation; these cases did not show any useful hybridisation signal even after 
prebleaching with 5% hydrogen peroxide according to the method described in 
chapter 2. In the positive cases, as with the FISH technique, there was no significant 
difference between the signal for FF tissues when compared with the corresponding 
GF tissues. All the controls showed good signal with CISH for both chromosomes.
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Figure 3.2 Fluorescence in situ hybridisation.
A: Gluteraldehyde fixed choroidal melanoma, hybridised with chrom osom e 3, 
show ing one copy (arrow) in m ost cells. B: Formalin fixed choroidal melanoma, 
hybridised with chrom osom e 3, show ing one copy (arrow) in m ost cells.
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Figure 3.3 Fluorescence in situ hybridisation.
A: Gluteraldehyde fixed retina (internal control) showing two copies of chromosome 
3 (arrow) in most cells. B: Same specimen after FISH, with negative signal for 
chromosome 3 in most tumour cells.
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3.5 Discussion
Fluorescence in situ hybridisation has increased in importance over the past decade 
as a powerful method for detecting DNA target sequences in cells from a wide 
variety of sources, including formalin fixed paraffin wax embedded tumour samples 
(McKay et al., 1997). Analysis of interphase nuclei from archival paraffin blocks 
eliminates the need for fresh tissue, allowing comparison of chromosomal anomalies 
with other prognostic factors.
Although the use of FISH in cytogenetics has improved the knowledge of 
chromosomal abnormalities in various pathological conditions, FISH has limitations 
when applied to archival paraffin embedded tissue samples. One limitation is the 
masking of relatively weak hybridisation signals by high levels of background 
autofluorescence (McKay et al., 1997). The background staining depends in part on 
the tissue endogeneous enzyme activity and if this is not blocked it can lead to 
unacceptable background labelling.
Formamide has been used to regulate stringency (an indicator of the approximate 
percentage of nucleotides that are coiTectly matched in the probe) and therefore 
reduce background staining but when formamide washes were incorporated into the 
protocol used in this study, they did not improve the quality of the hybridisation 
signals. Similarly the additional step utilised with the directly labelled probes has 
been shown to reduce background. Furthermore the directly labelled probes were 
easier to detect. In this study the directly labelled probes resulted in better 
hybridisation signals compared with the indirectly labelled probes.
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Another limitation in using FISH is related to the fixative used, which limits probe 
penetration. Most paraffin wax embedded tissues aie nowadays fixed in formalin 
which results in the formation of methlylene bridges between amino groups that 
reduce the penetration of nucleic acid probes (Chin et aL, 2003). Gluteraldehyde 
cross-links proteins more extensively, preventing probe penetration and requiring 
stronger unmasking procedures (Uehara et aL, 1993). Despite the different methods 
attempted in order to improve the quality of the signal, including commercial kits 
designed for use on fixed material obtaining consistent good quality signal in GF 
tissues remains a challenge.
FISH is therefore technically demanding when applied to archival material, 
particularly when fixed in gluteraldehyde. This technique has been applied to fresh 
tissue and slides prepared from disaggregated tumour cells usually fixed in formalin. 
However applying FISH on fresh material and disaggregated cells results in loss of 
histological architecture and potential sample contamination with non-tumour cells 
(Qian et aL, 1996). FISH analysis of paraffin-embedded specimens has been applied 
to other solid tumours in several different studies (Tanner et aL, 2000, Qian et aL, 
1996, Matsuta et aL, 1994, Chin et aL, 2003) but has not been reported in any 
previous study on sections of paraffin-embedded choroidal melanomas.
This study has shown that although FISH can be applied to paraffin embedded 
choroidal melanoma including GF specimens the results are inconsistent and appear 
to offer few advantages over CISH in the study of archival tissue. Following the 
results of this study the CISH technique has been used in the remaining studies 
described in this thesis.
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4 MONOSOMY 3 PREDICTS DEATH BUT 
NOT TIME TO DEATH IN CHOROIDAL
MELANOMA
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4.1 Background
The overall mortality from uveal melanoma is approximately 50% due to the 
development of liver métastasés. These métastasés are not usually evident when the 
primary tumour is treated and much current research has been conducted to identify 
reliable prognostic markers in primary uveal melanoma for early detection of high- 
risk patients whom prophylactic treatment would be justified. Specifically, 
monosomy 3 has been recognised to have a stronger association with a poor 
prognosis than do clinical and histological parameters and is in some series 
associated with a reduction in the 5-year survival time from almost 100% to only 
30% (Prescher et al., 1996). It is generally accepted that the peak mortality from 
metastatic disease from choroidal melanoma occurs within three years of diagnosis 
(Diener-West et al., 1992). However the clinical course of patients with uveal 
melanoma is unpredictable and a significant number of deaths still occur after 5, 10 
and 15 years. The occurrence of very late métastasés up to 36 years after initial 
surgery has also been described (Newton, 1965). To date the role of monosomy 3 in 
predicting time until death has not been assessed.
4.2 Specific Objectives
1 To confirm the prognostic value of monosomy 3 in predicting death caused by 
métastasés
2. To assess whether the presence of monosomy 3 can be predicted from tumour 
histology.
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3. To assess whether monosomy 3 is related to time until death caused by métastasés 
and whether life expectancy can be predicted in patients after surgical excision of a 
melanoma displaying monosomy 3.
4.3 Materials and Methods
4.3.1 study population
A total of 111 samples were studied; these were archival specimens from patients 
diagnosed with choroidal melanoma and obtained from Glasgow Western Infirmary 
Pathology files. They included sixty enucleations, 50 local resections (LRs) and 1 
exenteration. The patients were divided into two groups: group 1 (patients who had 
died from metastatic disease) and group 2 (patients alive or who had died from other 
causes after a minimum follow up period of 1 year-mean 16.85 years; range 1 to 30 
years). There were 71 cases in group 1, metastasising melanoma (MM), and 40 cases 
in group 2, non-metastasising melanoma (NMM). Follow up time was recorded from 
date of treatment to death or to last follow up. The surgery was performed between 
1974 and 1992 in patients with MM and between 1973 and 1991 in patients with 
NMM. Patients with MM were identified either from the cancer registry or case 
notes as having proven liver métastasés either by imaging, biopsy or post mortem 
examination. Patients with NMM were both alive and well or had a cause of death 
other than metastatic melanoma and no evidence of metastatic disease at last follow 
up. All tissues had been previously fixed in gluteraldehyde or formalin and 
embedded in paraffin wax.
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4.3.2 Clinical features
Clinical details were obtained from cases notes and the cancer registry. The details 
sought included age, sex, treatment of tumor, survival status and cause of death. The 
time to death was calculated from the date of local resection (LR) or enucleation. 
Survival status was determined up to August 2003. After obtaining these clinical 
details all samples were anonymised.
4.3.3 Histological features
Sections (4 p,m) were cut and stained with haematoxylin and eosin (H&E) and PAS 
without counterstain for light microscopy. The following histopathological 
parameters were assessed; cell type, extent of necrosis, maximum tumour dimension, 
extraoculai" extension, closed vascular loops, pigmentation, mitotic activity, retinal 
detachment and lymphocytic infiltration. The cell type was assessed according to the 
modified Callender classification (spindle, mixed, epithelioid) from a H&E stained 
section (McLean et aL, 1983). The presence of other cell types including balloon 
cells was also recorded. Pigmentation was described as amelanotic to low, 
intermediate, and strong pigmentation as defined in the COMS study (COMS, 1998 
a). The largest tumour dimension was recorded and the tumour classified as small, if 
less than 11mm; medium, 11 to 15 mm; and larger, greater than 15 mm. The extent 
of invasion was assessed as follows; rupture of Bruch's membrane, intrascleral 
channels (ISl), extraocular extension (EOX), optic nerve and orbital (noted at 
surgery). Information on ocular invasion was also obtained from the original 
pathology report.
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Closed vascular loops were assessed in PAS stained sections with the aid of a green 
filter as described by Folberg et al. (Folberg et al., 1993) and Foss et al. (Foss et al.,
1997). The number of mitotic figures per 40 high power field was counted. The 
extent of retinal detachment was graded into one of three categories: 1. no RD; 2. 
focal RD; detachment adjacent to tumour (detachment of neurosensory retina over 
and around the melanoma) or on the same side of tumour but not adjacent and 3. total 
RD: detachment of neurosensory retina with three to four quadrants of the retina 
involved. The exenteration specimen and the cases of local excision could not be 
assessed for RD. Semi-quantitative assessment of associated lymphocytic infiltration 
was as follows: none or minimal if there were none or only very few foci of 
inflammation; moderate if multiple foci were present and heavy if almost the entire 
tumour is involved.
4.3.4 Chromosome in situ hybridisation
The number of copies of chromosome 3 was assessed by CISH as described in 
chapter 2. Chromosome 18 was again used as a control chiomosome. In 20 
enucleation specimens normal retina was used as an internal control. In addition, 19 
cases of normal human skin (all GF) were included as an external control.
4.3.5 Statistical analysis
The relationship between metastasising melanoma and age, mitotic activity, tumour 
size and pigmentation was assessed by the Wilcoxon’s rank sum test. For the other
96
prognostic variables (monosomy 3, sex, cell type, intrascleral and extraocular spread, 
lymphocytic infiltration, presence of vascular loops, necrosis and RD), associations 
were assessed by Fisher’s exact test. Thep  value was corrected for the multiplicity of 
tests by the Holm’s method (Holm, 1979, Aickin and Gensler, 1996). The Holm’s 
method ensures that there is no false conclusion, compensating for the multiplicity of 
statistical tests. Multivariate analysis of several risk factors was based on a stepwise 
discriminant analysis, as implemented in the SPSS softwai'c package (SPSS Inc., 
Chicago, Illinois 60606). Survival time for a patient after surgical excision of a 
melanoma with monosomy 3 was compared with those balanced for chromosome 3 
using the two-sample t-test. Life expectancy for patients with tumours displaying 
monosomy 3 was predicted using a survival curve corrected for the patient’s age.
4.4 Results
4.4.1 Clinical and histological features associated with metastasising 
melanoma
The mean age of patients with MM was 57.8 years and 52.8 years for the NMM 
group (range 18-80 and 18-78, respectively). Patients with MM were slightly older 
than those with NMM but this difference was not statistically significant (p = 0.16 by 
the Wilcoxon Rank Sum Test). The male/female distribution was similar in both 
groups; group 1 (MM 1/1.03) and group 2 (NMM 1.11/1). There was no significant 
difference in the form of treatment between the two groups; group one included 37 
enucleations, 33 local resections and one exenteration and group two, 23 
enucleations and 17 local resections. The clinical-pathological features of MM and 
NMM melanoma are summarised in table 4.1 and the results of the univariate
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statistical analysis are shown in table 4.2. Using the more stringent Holm-adjusted p 
value the factors that were significantly associated with métastasés were mitotic 
activity, lymphocytic infiltration, presence of epithelioid cells, absence of balloon 
cells, presence of vascular loops, intrascleral or extraocular extension, tumour size 
and monosomy 3 (Table 4.2).
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Clinical or histological factor Statistical method used to 
test for association with 
métastasés
p value Holm- 
adjusted p 
value
Age W ilcoxon’s rank sum test 0.16 0.48
Sex Fisher’s exact test 0.769 1.00
Retinal detachment Fisher’s exact test 0.076 0.304
Presence of cystic spaces Fisher’s exact test 0.85 1.000
Pigmentation of tumour W ilcoxon’s rank sum test 0.042 0.210
Mitoses W ilcoxon’s rank sum test <0.001 <0.01
Lymphocytes in tumour Fisher’s exact test 0.000004 0.00005
Epithelioid cells Fisher’s exact test < 10"'° < 1.3 X 10-9
Balloon cells Fisher’s exact test 0.003 0.024
Loops Fisher’s exact test 0.0002 0.0022
Necrosis Fisher’s exact test 0.021 0.126
Invasion of surrounding tissue Fisher’s exact test 0.00647 0.0453
Size of tumour W ilcoxon’s rank sum test <0.001 <0.01
Missing chromosome 3 Fisher’s exact test 5.38X lO '" 7.5x10^3
Table 4.1 Clinical and histological factors tested for association with 
métastasés.
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Metastasising Melanoma 
n=7I
Non-metastasising Melanoma 
11=40
Age( mean) 57.8 years 52.8 years
Gender Male Female Male Female
36 35 19 21
Treatment Enucleation LR Exenteration Enucleation LR
37 33 1 23 17
Chromosome 3 1 Copy 2 Copies 1 copy 2 Copies
47 24 0 40
ChromosomelS 1 Copy 2 Copies 1 copy 2 Copies
0 71 0 40
Cell Type Epithelioid present Spindle Epithelioid present Spindle
57 14 7 33
Balloon Cells Yes No Yes No
7 64 13 27
Necrosis Yes No Yes No
23 48 3 37
Pigment None-low Moderate Heavy Low-low Moderate Heavy
36 25 8 27 12 1
Lymphocytes None-low Moderate Heavy None-low Moderate Heavy
59 8 4 38 2 0
Invasion No ISI EOX No ISI EOX
32 21 18 23 14 2
Mitoses <5 >5 >10 <5 >5 >10
53 15 3 38 1 1
Loops Yes No Yes No
39 32 8 32
Size <llnim ll-15mm >15inm <llmm ll-15mm >15mm
8 16 47 10 15 15
Retina No Focal Total No Focal Total
Detachment 0 11 26 1 6 9
Table 4.2 Clinical and histological parameters of metastasising and 
non-metastasising choroidal melanomas.
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Multivariate analysis was then performed to determine which of these interrelated 
variables were independently related to outcome. The following factors (in their 
order of satisfying the criterion for addition to the model) were significantly 
associated (p<0.0001) with metastasising melanoma: monosomy 3, presence of 
epithelioid cells, lymphocytic infiltration and tumour size > 15mm. From a 
knowledge of these four factors, 89% of the tumours could be correctly predicted to 
be from group 1 (MM) or group 2 (NMM).
4.4.2 Association of monosomy 3 with metastasising melanoma
Monosomy 3 was detected in 47 of the 71 cases of MM (66.1%) and was 
significantly associated with metastases-related death (p = 0.0001). The remaining 24 
MM and all 40 NMM had two copies of chromosome 3 and therefore defined as 
balanced.
4.4.3 Prediction of monosomy 3 from clinical and histological features
Multivariate discriminant analysis of the histological features of both MM and NMM 
indicated that the presence of epithelioid cells and vascular loops were statistically 
significant predictors of monosomy 3, when considered together. Both satisfied the 
confidence criterion p<0.0001. The discriminant function derived gave the correct 
prediction of chromosome number in 70% of cases.
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4.4.4 Prediction of survival time in tumours with monosomy 3
Among the 71 patients in group 1 (MM), 47 displayed monosomy 3, with a mean 
survival time of 4.31 years ±2.83 yeais (SD). The remaining 24 cases with 2 copies 
of chromosome 3 had a mean survival time of 4.21 ±3.34 years. There was no 
significant difference in time until death of those with tumours with monosomy 3 
compared with those with 2 copies of chromosome 3 in this group (p = 0.90) (Figure 
4.1).
4.4.5 Prediction of life expectancy of patients after excision of a 
melanoma displaying monosomy 3
All 47 patients with melanomas displaying monosomy 3 had died. The mean survival 
time was 4.3 years (median, 3.5). The survival curve, corrected for the patient’s age 
at the time of surgery and based on the assumption of a linear relationship, suggests 
that very long term survival with monosomy 3 is rare (Figure 4.2).
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Figure 4.1 Time from surgery to death of patients with metastasising 
melanoma.
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Figure 4.2 Survival plot corrected for the patient’s age at time of 
surgery.
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4.5 Discussion
Monosomy 3 has been shown by many investigators to be associated with death from 
métastasés after treatment of uveal melanoma (White et al., 1998, Sisley et al., 1997, 
Sisley et al., 2000, Scholes et al., 2001, Scholes et a l, 2003, Prescher et a l, 1996, 
Fatel et a l,  2001, Naus et a l,  2002, Aalto et a l, 2001), Using the technique of 
chromosome in situ hybridisation described in chapter 2, and applying the same cut 
off points to this larger series, the findings of these previous studies has been 
confirmed. In this study monosomy 3 was identified in 66.1% of melanomas that 
caused death from métastasés. Previous studies have identified monosomy 3 in 50 to 
73% of choroidal melanomas (Aalto et a l,  2001, Scholes et a l, 2001, Patel et a l, 
2001, Scholes et a l, 2003, Prescher et a l, 1996, Sisley et a l, 1997). It is not possible 
however to directly compare these values, as unlike some of these studies the data set 
was selected on the basis of death or survival from uveal melanoma and is therefore 
not considered to be as representative of all cases of choroidal melanoma.
Although monosomy 3 was confirmed as a significant predictor of metastases-related 
death, a second smaller but significant group of patients who died of metastatic 
melanoma even though their tumours contained 2 copies of chromosome 3 was 
identified. There are several possible explanations for this. First, this is a 
retrospective study that includes samples from the 1970s. Samples may therefore 
have been included from patients who would now be treated without surgery. 
Without tissue samples, patients with similar tumours could not be included in other 
studies. These differences may also be related to the CISH technique used in this 
investigation, since the probes are centromere specific, and regional losses of 
chromosome 3 would not be detected. However in previous studies in which other
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techniques were used, including microsatellite analysis and comparative genomic 
hybridisation, investigators found that in most cases the entire copy of chromosomeS 
is lost and that regional loss occurs in only a minority. (Tsechentscher et al., 2001, 
Prescher et al., 1996, Sisley et al., 1997, White et al., 1998, Scholes et al., 2001). 
Furthermore, the prognostic significance of these regional losses is unclear. Scholes 
et al. (Scholes et al., 2003) identified loss of heterozygosity of chromosome 3 in 60 
cases; of these, 6 cases showed only regional losses. Five of these six patients were 
alive at the end of the 4-year study period, suggesting that these partial deletions may 
not carry the prognostic significance of complete loss of heterozygosity. It is also 
possible that this technique has failed to identify a small subclone of cells, within the 
tumor, displaying monosomy 3. However the presence of subclones of cells is more 
likely to be identified using CISH compared with standard cytogenetics, as a whole 
histological section of the tumour is studied and not just selected cells that have been 
successfully cultured and identified in a metaphase spread. Finally, and probably 
most likely, there may be other alterations that are important in the development of 
métastasés in choroidal melanoma. These may include other as yet unidentified 
cytogenetic abnormalities or may be related to alterations in tumour biology that 
allow invasion and métastasés. The metastatic cascade involves a series of events 
including detachment of tumour cells from each other followed by both attachment 
to and degradation of the extracellular matrix, thus allowing migration of tumour 
cells. As mentioned above, an increase in the risk of métastasés has been shown with 
loss of expression of intercellular cell adhesion molecule-1 (Anastassiou et a l, 2000) 
and conversely with expression of al-and a4 -integrins (Woodward et al., 2005). 
MMPs may also play a role in degrading the extracellular matrix, particularly with 
increased expression of matrix metalloproteinase-2 (Vaisanen et al., 1999). The
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molecular mechanisms that lead to the metastatic phenotype in choroidal melanoma 
are not fully understood but may be related to isolated point mutations in relevant 
genes or their promoters, so that they would not be detected in chromosomal studies.
In this retrospective study, there were 71 patients who died from métastasés, with 
time from surgery to death ranging from 4 months to 14 years; two thirds of these 
had tumours displaying monosomy 3 and a mean survival time of 4.31 years; the 
remaining third were apparently balanced for chromosome 3 and had a mean survival 
time of 4.21 years. There was no significant difference in time to death between the 
two groups (Figure 4.1). This study has also shown that survival beyond 10 years is 
possible but rarely occurs in patients with a tumour displaying monosomy 3. Because 
some of the patients were identified from a database in which they were only 
included after death, it is possible that very long-term survivors may be 
underrepresented in this data, with consequent underestimation of survival time. 
However using a survival curve to predict life expectancy of these patients suggests 
that very long-term survival with monosomy 3 is probably rare, and as such this bias 
will be small.
In this study the presence of monosomy 3 could be partly predicted from tumour 
histology. Specifically, the presence of epithelioid cells (p<0.001) and closed 
vascular loops (p<0.001) were significantly associated with monosomy 3 when each 
characteristic was considered individually. When these two histological 
characteristics were included in a multivariate predictive model, the predictions were 
correct in 70% of cases. Scholes et a l (Scholes et a l, 2001) also showed a statistical 
association between monosomy 3, closed vascular loops and epithelioid cells
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however using a forward stepwise logistic regression model they showed that 
monosomy 3 could only be reliably predicted in patients with large epithelioid 
tumors (Scholes et a l, 2003). In this study large tumor size (>15mm) was not a 
significant predictor for monosomy 3. The distribution of tumor sizes was similar in 
this study to that of Scholes et a l  (Scholes et a l, 2003) and it is therefore unlikely to 
represent sample selection. Other researchers have shown no association of 
monosomy 3 with histopathological features (Prescher et a l, 1996, Sisley et a l, 
1997, White et a l, 1998).
In this study, in the univariate model analysis, infiltration of the tumour by 
lymphocytes was also significantly associated with métastasés (p = 0.000004 by 
Fisher’s exact test), which is in keeping with previous research (de la Cruz et a l, 
1990). In the multivariate analysis, the presence of lymphocytic infiltration ranked 
fourth as a predictor for survival, when compared with presence of monosomy 3, 
epithelioid cell type and large size tumours. Conversely, lymphocytic infiltration in 
the COMS study did not appear to be an independent prognostic factor. This study 
also showed that spindle cell type tumours had the least inflammation and epithelioid 
cell tumours the greatest degree of inflanamation (COMS, 1998 a). In this series, 
considering that cell type and tumour size were dominant factors in patient survival, 
it would be reasonable to assume that the majority of the poor prognosis for tumours 
with lymphocytic infiltration should be the result of associations with cell type and 
tumour size.
According to Kivela et a l  tumour size and microvascular loops are strong predictors 
of exudative RD (Kivela et a l, 2001). In this study, RD was not convincingly related
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to any of the other tumour characteristics; specifically tumour size and vascular 
loops. This study was also limited by the fact that in more than 50% of the cases 
retina wasn’t available because LRs were carried out; for this reason RD was 
excluded from the stepwise analysis to predict monosomy 3 from the histology.
In conclusion, this study confirms that monosomy 3 in choroidal melanoma is a 
significant predictor of métastasés related death. However death from metastatic 
melanoma occurs in a significant number of cases that do not display monosomy 3, 
suggesting that other molecular events aie important in the metastatic cascade in 
these patients. Furthermore, this emphasises a cautious approach to the use of 
cytogenetic studies for patient counselling. In this study the presence of monosomy 3 
could be correctly predicted in up to 70% of cases by the presence of an epithelioid 
cell component and vascular loops, but it was not related to tumour size. In patients 
with métastasés, there was no difference in time until death in those with tumours 
displaying monosomy 3 compared with those tumours that had two copies of 
chromosome 3. However as with all MMs, life expectancy in patients with tumours 
displaying monosomy 3 is generally short.
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5 CORRELATION OF HETEROGENEITY 
FOR CHROMOSOME 3 COPY NUMBER 
WITH CELL TYPE IN CHOROIDAL 
MELANOMA OF MIXED CELL TYPE
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5.1 Background
The majority of previous cytogenetic studies have considered uveal melanoma as a 
homogeneous entity utilizing DNA extracted from whole tumours or performing 
classical cytogenetics performed on selected samples of tumour cells. However 
morphological heterogeneity is well recognised in uveal melanoma. The majority of 
tumours are composed of variable proportions of epithelioid and spindle-shaped cells 
(COMS, 1998 a). There have been few studies of cytogenetic heterogeneity in uveal 
melanoma. Monosomy 3 has been associated with a reduction in the 5-year survival 
from 100% to 30% due to metastatic death (Prescher et a l, 1996). Therefore, 
cytogenetic heterogeneity carries significant clinical implications for the sampling of 
tumours for cytogenetic studies.
5.2 Specific Objectives
1. To evaluate the presence of cytogenetic heterogeneity for chromosome 3 in 
choroidal melanomas with morphologically distinct spindle and epithelioid cell types 
using the technique of chromosome in situ hybridisation on archival paraffin 
embedded tissue.
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5.3 Materials and Methods
5.3.1 Study population
Sixty four cases of choroidal malignant melanoma of mixed cell type (modified 
Callender system) (McLean et al., 1983) were identified from the eye pathology 
files, Western Infirmary, Glasgow, between the years 1975 and 2002. From these 64 
tumours the cases where the populations of spindle and epithelioid cells were 
relatively discrete were identified. All tissues had been previously fixed in 
gluteraldehyde or formalin and embedded in paraffin wax.
5.3.2 Survival status
The survival status of the patients and cause of death were obtained from cases notes 
and the cancer registry. The time to death was calculated from the date of treatment, 
and survival status was determined up to August 2003.
5.3.3 Chromosome in situ hybridisation
The number of copies of chromosome 3 was assessed by CISH using chromosome- 
specific centromeric probes, as previously described. Chromosome 18 was the 
control chromosome. Copy number of chromosome 3 was assessed in both spindle 
and epithelioid areas. A minimum of 200 nuclei were counted in both spindle and 
epithelioid areas. Chromosome number was assessed using both chromosome index 
and signal distribution as described above. Briefly, Cl gives an average chromosome
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copy number and is calculated by dividing the number of hybridisation sites by the 
number of nuclei counted. Chromosome loss is defined as a Cl less than 3 standard 
deviations from the mean for retina (normal tissue). The SD is defined as the 
percentage of nuclei with only one hybridisation site. A signal distribution of more 
than 60% was the cut off point used to define chromosome loss. The tumour regions 
had to show chromosome loss by both Cl and SD to be regarded as monosomie. The 
cut-off points were selected in accordance with our laboratory’s previous experience 
of the technique.
5.3.4 Statistical Analysis
The relationship of pattern of monosomy 3 distribution with tumour diameter, age 
and survival was tested by pairwise t-test and pairwise rank sum test.
5.4 Results 
5.4.1 study population
Twenty-two suitable cases were identified from the original group of 64 mixed 
choroidal melanomas. Nineteen of the cases were from patients who had died from 
metastatic melanoma and 3 were from patients alive or dead from other causes.
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5.4.2 Chromosome 3 copy number in spindie and epithelioid areas
The tumours separated into 3 groups based on the copy number of chromosome 3 in 
spindle and epithelioid areas. Ten (45%) melanomas displayed two copies of 
chromosome 3 in both spindle and epithelioid cells and were defined as balanced for 
chromosome 3 (BB). This included the 3 cases where the patients were alive or dead 
from causes other than métastasés. Five (23%) displayed monosomy 3 in both 
spindle and epithelioid cell areas (M3M3). In the remaining 7 cases (32%) the 
epithelioid areas displayed monosomy 3 but the spindle cell areas contained 2 copies 
of chromosome 3 (M3B) (Figure 5.1).
5.4.3 Statistical analysis
The pattern of monosomy 3 (BB, M3M3, M3B) was not significantly related to 
clinical features of the patients such as tumour size, age at surgery or time to death.
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Figure 5.1 Heterogeneity for chromosome 3 in a mixed ceil tumour.
A: Large choroidal m elanom a with poorly pigm ented epithelioid nodule (e) and more 
heavily pigm ented spindle cell area (s) (H & E ,x l) , B & C: High power view  from  
the epithelioid and spindle areas, respectively (both H & E, x400). D: Chrom osom e 
in situ  hybridisation for chrom osom e 3 in epithelioid cells. The round cell 
m orphology is still evident and the majority o f  cells show only one hybridisation site 
(single arrows) (Chrom osom e 3, x400), E: Chrom osom e in situ  hybridisation for 
chrom osom e 3 in spindle cells. The spindle cell m orphology is still evident and the 
majority o f cells show two hybridisation sites (double arrows) (chrom osom e 3, 
x400).
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5.5 Discussion
Monosomy 3 in choroidal melanoma is a significant predictor of métastasés related 
death and has been associated with a reduction in the 5-year survival from 100% to 
30% (Prescher et al., 1996). Although monosomy 3 is an important predictor of 
metastatic death we have previously shown that there is also a small but significant 
number of people with metastasising melanoma whose tumours are balanced for 
chromosome 3. One possible explanation for our cases of metastasising melanoma 
without monosomy 3 is the presence of genetic heterogeneity. Morphological 
heterogeneity of choroidal melanoma is well recognised with the majority of cases 
being of mixed cell type (Mooy and De Jong, 1996, COMS, 1998 a). The objective 
of this study was to evaluate corresponding loss of heterozygosity of chromosome 3 
in areas of spindle and epithelioid cell type using CISH. In 23% of all melanomas, 
monosomy 3 was identified in both spindle and epithelioid cell areas whereas in 32% 
it was present only in the epithelioid cell areas. Forty five percent of melanomas 
were balanced in both spindle and epithelioid areas. This latter group included 7 
cases of metastasising melanoma. Therefore, cytogenetic heterogeneity for 
chromosome 3 does not explain métastasés in cases balanced for chromosome 3 in 
both spindle and epithelioid areas. White et al. have previously reported a case of 
clonal heterogeneity in a uveal melanoma. In this case the tumour was found to have 
distinct pigmented and non-pigmented areas on gross examination (White et al.,
1998). Tissue samples were collected from both of these areas for standard 
cytogenetics. Histological examination revealed small regular epithelioid cells in the 
pigmented area and large pleomorphic epithelioid cells in the non-pigmented area. 
Standard cytogenetic analysis showed 2 copies of chromosome 3 in the pigmented 
area compared with monosomy 3 in the non-pigmented area. It is notable that gross
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differences in pigmentation are not frequently present to alert the sampler to 
morphological and cytogenetic heterogeneity when cells are to be cultured for 
standard cytogenetics. Techniques that involve extraction of DNA from tissue 
sections should theoretically represent the tumour cell population more accurately 
(Aalto et al., 2001, Tsechentscher et a l, 2001, Scholes et a l, 2001, Scholes et a l, 
2003, Parrella et a l, 1999). However some subclones or even contaminating normal 
DNA may be preferentially amplified during polymerase chain reaction. The CISH 
technique differs from other technique used to assess monosomy 3 because 
chromosomal losses are assessed in both interphase and metaphase nuclei within a 
population of cells in a tissue section. This allows the direct correlation of genotype 
with phenotype.
In this study I selected tumours with discrete populations of spindle and epithelioid 
cells to aid counting of the different areas. The CISH technique can only be applied 
to a defined population of tumour cells and the assessment of chromosomal loss 
cannot be made on individual tumour cells. These 22 cases were selected from 64 
choroidal melanomas of mixed cell type. This supports the impression that such 
morphological subclones are not uncommon. However since this does not represent 
our entire archive there may be an element of selection bias. In the other 42 tumours 
there were insufficiently large areas of each cell type to allow accurate counting.
Although the number of cases studied was small we have demonstrated heterogeneity 
for chromosome 3 copy number in 7 of 22 (32%) cases. This has important 
implications for other methods of cytogenetic analysis such as short-term culture for 
metaphase spreads, since often only a sample of tumour is submitted for analysis. For
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example, a small biopsy of the tumour may be taken before submitting the remaining 
tumour for histopathological examination (Sisley et al., 1997, Horsman and White, 
1993).
Since the importance of cytogenetic assessment of uveal melanoma will increase as 
new therapies become available tumours may be biopsied by FNA in order to obtain 
cytogenetic information prior to treatment with modalities other than surgery 
(Damato, 2004). The possibility of morphologically non-representative material in 
FNA has already been reported by Folberg et al. in a study comparing average 
nucleolar area in FNA with enucleation specimens of uveal melanoma (Folberg et 
a l, 1985). Similarly Augsburger et al. demonstiated a needle track that just missed 
an epithelioid region in a tumour removed after FNA (Augsburger et al., 1985). 
Based on the results of this study the confidence attributed to any prognostic 
assessment undertaken on a small sample of tumour would be greater if a 
morphological assessment showed the tissue sampled to contain epithelioid cells.
In conclusion, mixed choroidal melanomas with discrete spindle and epithelioid cell 
populations may display heterogeneity for chromosome 3 copy number that 
correlates with populations of different cell type. CISH is a useful technique to 
identify this clonal heterogeneity in excision specimens. However the genetic 
information obtained from small samples using other techniques such as classical 
cytogenetics may not be representative. This in turn will affect the degree of 
certainty in patient counselling and potentially patient selection for novel treatments.
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6 FINAL DISCUSSION
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6.1 Summary
This thesis describes the adaptation of the technique of chromosome in situ 
hybridisation to assess chromosome 3 copy number in choroidal melanoma, and the 
utilisation of this to study the presence of monosomy 3 in an archival series. The 
findings were interpreted in conjunction with histological features, survival and time 
to death. This in-situ method of assessing chromosomal changes in tumours has both 
advantages and disadvantages compared with other techniques, and these studies 
utilising CISH have provided additional information on chromosome 3 changes in 
choroidal melanoma.
The main advantage of CISH is that it is applicable to archival material. This is 
important for the study of tumours such as choroidal melanoma. Choroidal 
melanoma is a relatively rare tumour so retrospective studies are likely to include 
larger numbers than prospective studies. In addition, the majority of tumours are 
currently dealt with using vision sparing techniques such that tissue is not often 
available for cytogenetic analysis. Therefore study of archival tissue may give a 
better cytogenetic picture of choroidal melanoma as a whole.
Choroidal melanoma is renowned for the occurrence of very late métastasés which 
may take many years to reveal themselves and these late metastasising tumours may 
not be recognised in prospective studies with only a 3 to 5 year follow up. Another 
advantage of CISH is that it allows the direct correlation of chromosomal changes 
with histology. This is helpful for choroidal melanoma where there are clearly 
defined cell types (spindle and epithelioid) which have been shown in numerous 
previous studies to correlate with prognosis.
119
CISH does, however, presents some limitations. The adaptation of CISH for 
choroidal melanoma, which in archival tissue is often gluteraldehyde fixed, has 
required relatively rigorous pretreatments. Despite pre-bleaching I was unable to 
obtain adequate signal in some heavily pigmented tumours. The counting technique 
is time consuming and requires a certain amount of experience. In addition to these 
practical problems, and contrary to some other techniques, fine mapping of changes 
or characterisation of specific tumour suppressor genes that may be involved cannot 
be achieved with CISH.
CISH is only applicable to a defined tumour population and not to individual tumour 
cells. This is because of the effects of nuclear truncation which explains why some 
cells will contain only 1 spot even if they aie disomie. Other cells will appear 
polysomic during mitoses. Nonetheless the advantages of CISH allow the assessment 
of monosomy 3 in choroidal melanoma from a different perspective to that 
previously cited in the literature.
Having developed the technique of CISH for archival choroidal melanoma, I 
attempted the technique of FISH to assess if this would offer any advantages over 
CISH. Theoretically, FISH has the advantage of allowing the use of multiple 
fluorochromes and therefore the detection of more than one chromosome in one 
tissue section. However despite rigorous preheatments I was not able to obtain 
consistent results with FISH. This can be explained by the many recognised 
limitations of FISH when applied to archival paraffin tissue samples. It is well 
recognised that poor probe penetration is a problem in gluteraldehyde fixed tissue 
although I was able to obtain good signal in 8 cases. Another common problem with
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FISH is the presence of background autofluorescence. In many tumours this is 
commonly due to the effects of endogenous enzyme activity. In addition 
pigmentation in choroidal melanoma may cause problems with background 
autofluorescence. The above limitations reflect many of the problems already 
encountered in the literature and this may be why it has only previously been 
reported on disaggregated tumour cells (Patel et a l, 2001, Naus et a l, 2002, Naus et 
a l, 2001). This study confirmed that CISH was a more consistent and effective 
technique to apply to an archival series of choroidal melanoma.
In the first study I identified 2 patient groups with choroidal melanoma. The first 
group represented those where death from metastatic choroidal melanoma had been 
recorded. The second represented those who were alive or had died from other 
causes following primary treatment of choroidal melanoma. This study confirmed the 
work of previous studies that monosomy 3 is associated with poor survival. As 
previously discussed it is not possible to directly compare the results obtained with 
CISH with other techniques. In addition, the relative biases introduced by case 
selection in a retrospective study means that results are difficult to compare with 
other studies which all contain an element of bias. For example many prospective 
studies include only melanomas for which primary treatment has failed or large 
tumours that required enucleation. Many small tumours aie now dealt with by vision 
sparing techniques and as such tissue is not available. Significantly as the cases in 
this retrospective study were selected on outcome it was possible to identify a small 
but significant number of patients with disomy 3 who died from metastatic 
melanoma, suggesting that other molecular events are important in tumour invasion 
and metastatic cascade. In addition, this study showed that monosomy 3 does not
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correlate with time to death as there was no significant difference in time to death 
between patients with MMs containing one or two copies of chromosome 3 and 
survival beyond 10 years (with the longest time reaching 14 years). This study also 
found that several histological features correlated with monosomy 3; specifically, 
monosomy 3 could be partly predicted by the presence of epithelioid cells and closed 
vascular loops. These results have important implications for screening because 
given that patients without monosomy 3 are not ensured survival this means that 
there is an increasing need for a suitable screening method that can identify and 
follow up those tumours that caiTy a high risk of metastasising. Furthermore, if 
patients with monosomy 3 may still survive up to 14 years, elderly patients at time of 
diagnosis may make additional screening and therapies undesirable.
The majority of tumours are treated by some form of vision sparing technique, and if 
cytogenetics is to be performed as part of the prognostic/therapeutic work up some 
form of biopsy may be required. In the second study, using CISH, I showed that 
monosomy 3 was heterogeneous in a subpopulation of choroidal melanomas. The 
majority of cytogenetic techniques, contrary to CISH, do not assess cell type in 
conjunction with the cytogenetic abnormalities and clearly this is important. A cell 
block preparation made from a fine needle aspirate wash-out or the recently 
described microbiopsy technique (Sen et a l, 2006) would allow the assessment of 
cell morphology in conjunction with assessment of monosomy 3 (using any 
recognised technique). Based on the results of this study in a biopsy composed 
purely of spindle cells the presence of 2 copies of chromosome 3 would therefore 
carry less prognostic significance than one containing both spindle and epithelioid 
cells. CISH is therefore a useful technique to prove heterogeneity of monosomy 3
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with cell type. The technique can however only be applied to a defined population of 
tumour cells since the assessment of chromosomal loss can not be made on 
individual tumour cells.
Although CISH may not be the technique of choice for screening there are not any 
other described techniques, of which I am aware, that can assess the individual cells, 
cytogenetic and morphological make up.
It has also been suggested that cytogenetic screening will allow patients a better idea 
of outcome and it will also help to rationalise scarce NHS resources. However the 
best way to do this is still not clear. Whilst it is entirely possible that an FNA could 
capture both monosomie and disomic subclones, the operator could not be certain 
that a monosomie epithelioid subclone had not been missed. Furthermore, the 
majority of patients still do not have their tumours biopsied and the question whether 
these patients should have it done remains. Disomy 3 does not mean definite survival 
and the presence of clonality within a tumour has implications for screening methods 
such as FNA. Whether it would be appropriate to limit more invasive biopsy to those 
that have undergone surgery is yet another unknown but again these are a minority. 
Such an approach would have implications for the assessment of the less invasive 
technique of FNA, if applied as a screening method.
In conclusion, CISH is an alternative method to assess chromosomal gains and losses 
in choroidal melanoma. Like other techniques it has both advantages and 
disadvantages. Acknowledging these and capitalising on the advantages it has proven 
a useful tool for the study of monosomy 3 in archival choroidal melanomas.
123
6.2 Further studies
This thesis has raised several questions that could form the basis of future research 
projects.
Firstly, I identified a group of melanomas that caused death by métastasés, yet did 
not show monosomy 3. Further genetic studies such as CGH using tumour and 
normal DNA samples, simultaneously hybridised to normal metaphase 
chromosomes, would be worthwhile on this group to see if there were any common 
features and to exclude or identify other cytogenetic causes. There is also increasing 
evidence for the involvement of alternative mechanisms at the molecular level in the 
development of métastasés in choroidal melanoma. Some of the molecular targets 
involved are cell adhesion molecules, growth factors and matrix metalloproteinases. 
A more detailed study of these prognostic factors may guide therapeutic strategies, 
including drug design.
It is assumed that tumour progression in patients with monosomy 3 is due to loss of 
TSGs but it is still not known what these genes are. Further areas of study might 
include the identification of the specific genes and pathways involved, directly or as 
a result of inactivation of rran^-acting factors following loss of chromosomal 
material. Thus molecular studies may provide information about genes that are 
overexpressed in choroidal melanoma and activated in mitogenesis and which could 
be potential targets for the treatment of micrometastases.
Secondly, I identified clonal heterogeneity in a subgroup of tumours with distinct 
subpopulations. Whilst in my experience tumours with these defined areas of
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epithelioid and spindle cells are relatively common, there are still more tumours with 
truly mixed populations of cell types. After identifying the presence of monosomie 
subclones in choroidal melanomas it may be of interest to examine how small these 
clones can be and what size a clonal population has to be before it carries a poor 
prognosis. This is difficult to answer and is certainly not possible with the CISH 
technique since a clonal population could range from 1 up to many thousands of 
cells. Whilst cell morphology can be viewed by the CISH technique, a result as 
applied to an individual cell is meaningless. The answer to these questions regarding 
clonal population size may answer many of the questions regarding the role of biopsy 
in screening and how to assess if a tumour sample is representative. Assessment of 
this will require alternative techniques. For example, small group of cells could be 
removed using a laser capture microdissection system and after extraction of DNA a 
PCR based approach could be used to amplify relevant areas on chromosome 3.
Ultimately this is a relatively raie tumour for which there is currently no effective 
tieatment for metastatic disease. However with further advancement in treatments it 
may become increasingly important to identify patients who are at risk of metastatic 
disease. Whilst there is potential for cytogenetic screening to identify these ‘at risk’ 
patients further research on the best technique to undertake this is required. As with 
all screening techniques it is improbable that any technique will identify all patients 
at risk of métastasés however early recognition and treatment could alter the course 
of the disease for many patients and the possibility of such treatment would certainly 
be a prerequisite for offering screening.
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Finally, the mechanistic implications of monosomy 3 in the development of 
choroidal melanoma remains to be fully understood using traditional research 
methodology. However, loss of all or part of chromosome 3 seems to suggest that 
one or more tumour suppressor genes involved in the development of choroidal 
melanoma are located in this choromosome. Furthermore, minimal regions of 
abnormalities have been described (Parrella et ah, 1999, Tsechentscher et a l, 2001) 
and although the exact role of these areas in the development of uveal melanoma is 
not clear, they might harbour important “candidate genes”. Identifying those 
important discriminating genes and understanding the changes occurring that lead to 
métastasés is currently the subject of intense investigation.
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